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Subcutaneous (SC) route is important for administration of various therapeutic proteins 
(TPs) like monoclonal antibodies (mAbs), human growth hormone (hGH), insulin, and 
recombinant subunit vaccines. The SC route has advantages like shorter clinical visits for patients, 
the possibility of self-administration, and its less invasive nature compared to the intravenous (IV) 
route. However, SC route has a challenge of incomplete bioavailability for various TPs, especially 
mAbs (52-80%). After SC administration, the mAbs travel through the lymphatic vessels and 
lymph nodes (LNs) before reaching the systemic circulation. Proteolysis at the SC injection site 
and within the lymphatic system may be partially responsible for the reduced bioavailability of 
mAbs. Chapter 2 of this dissertation describes a top-down mAb physiologically based 
pharmacokinetic (PBPK) model which was used to estimate the lymphatic trunk-LN clearance 
using the human SC pharmacokinetic (PK) data from published clinical trials. Iron oxide 
nanoparticles (IONPs) may originate from equipment used in the manufacturing of TPs or from 
needles during the SC injection. The IONPs may alter the secondary structure and the degree of 
oxidation of TPs. Therefore, Chapter 3 of this dissertation looks at the effect of IONPs on the TP 
stability. In Chapter 4, midazolam (MDZ) metabolism and PK were reported in the healthy and 
inflammatory disease condition in mice. Finally, a bottom-up minimal PBPK model was used to 
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Chapter 1 : Introduction 
Monoclonal antibodies (mAbs), human growth hormone (hGH), insulin, recombinant 
subunit vaccines and various other proteins are important therapeutic proteins (TPs) (1). The TPs 
are mainly administered via intramuscular (IM), subcutaneous (SC) and intradermal (ID) routes 
due to convenience compared to the intravenous (IV) route (2). However, incomplete 
bioavailability is a major disadvantage for the TPs (3). Proteolysis at the SC injection site and in 
the lymphatic system is a major elimination pathway for the TPs and is responsible for reduction 
in their bioavailability (3-6). The needle penetration in the skin and SC tissue can promote 
secretion of proteolytic enzymes by various cells into the extracellular matrix (interstitial space). 
The SC injection site consists of cells like adipocytes, fibroblasts, T cells, lymphocytes, mast cells, 
dendritic cells (DCs) and macrophages, which contribute towards proteolysis of the TPs (Figure 
1.1). The SC tissue has a low level of basal proteolytic activity; however, the penetration of an 
injection needle and the subsequent hydrostatic pressure due to the injection volume can alter the 
SC tissue leading to secretion of serine proteases, threonine proteases, and metalloproteases by the 
tissue matrix, DCs, and other SC tissue cells (7, 8). Finally, intracellular processes like proteasomal 
catabolism after ubiquitin binding and lysosomal degradation may also lead to reduced 
bioavailability of the TPs (7, 9, 10). In addition, immune reactions (e.g. generation of antibodies 
against the administered TP, allergy, anaphylactic reaction, accumulation of immune cells around 
the injection site) can enhance the proteolytic activity in SC tissue. These immune reactions are 
caused by the presence of non-self antigens, partially degraded (e.g. oxidized or deamidated) TP, 




Along with the SC injection site, the lymphatic system can also play a vital role in 
proteolysis of the TPs. Proteins with molecular weight greater than 16-20 kDa are usually absorbed 
at least partially via the lymphatic capillaries upon SC administration (3, 11, 12), from which they 
are trafficked through the lymphatic vasculature and lymph nodes before entering the systemic 
circulation at the junction of the left subclavian vein and internal jugular vein or at the beginning 
of left brachiocephalic vein. The lymph nodes (LNs) are predominant sites of antigen presentation, 
because the nodal sinuses are large populations of antigen presenting cells (APCs), naïve and 
mature B and T cells. The structure of LNs is responsible for a molecular sieving of passing 
materials, resulting in extensive interaction of proteins with the APCs (3, 13-15). Therefore, the 
endocytic uptake and lysosomal degradation may contribute towards the loss of TPs in the LNs. 
In addition, the immune cells in the lymphatic system may secrete protease enzymes (16) leading 
to increased proteolysis of the TPs. Hence, the lymphatic system plays a major role in proteolysis 
of the TPs and reduction in their bioavailability (3, 13-15). 
 
Figure 1.1: Physiological processes at the SC injection site 
a) Migration of DCs from the dermis to SC tissue due to penetration of the SC injection needle. b) Potential 
oxidation of the TP by the ROS. c) Proteolytic and lysosomal degradation of the TP in the SC interstitial and 
intracellular compartments. d) Uptake of the TP by the lymphatic capillaries (lymph flow) and blood vessels (blood 
flow). (TP: Therapeutic protein, O-TP: Oxidized TP, DC: Dendritic cells, M: Macrophages, ROS: Reactive oxygen 
species, PD: Proteolytic degradation, LD: Lysosomal degradation, SCC: Subcutaneous cells). 
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The oxidation of TPs is another metabolic process responsible for their degradation in the 
skin, SC tissue and lymphatic system. The oxidation may lead to undesirable effects like altered 
biological activity, increased immunogenicity, modified secondary and tertiary structure of the TP, 
increased aggregation potential, altered pharmacokinetics (PK), and decreased neonatal Fc 
receptor (FcRn) binding affinity for the mAbs (17, 18). The amino acids like methionine, 
phenylalanine, tryptophan, tyrosine, histidine, cysteine are prone to oxidation by hydrogen 
peroxide and superoxide radicals produced by respiratory bursts of immune cells, especially the 
monocytes and neutrophils (19). Furthermore, cellular damage, e.g. physical rupture by the 
injection needle, osmotic and hydrostatic stress, can generate signals of wounding which include 
secretion of proinflammatory cytokines (IL-1b, TNF-α and IL-6). In addition, DCs and 
macrophages can initiate an innate immune response. The DCs and macrophages continuously 
ingest proteins within the tissue and display protein fragments as potential antigens. Localized 
irritation and immune reactions are frequently observed in the SC tissue after injection of the TPs. 
Mast cell population is approximately 7000/cm3 and can be responsible for immune response 
against allergens possibly present in the TP formulation (7). A specialized subpopulation of DCs 
termed as the langerhans cells (LCs) reside in the epidemis. The LCs constitute around 1% of the 
total epidermal cell population; however, they occupy approximately 20-25% of the surface area. 
Various cells in the SC tissue are also involved in the adaptive immune response and antigen 
presentation to naïve T cells in the LNs (20-22). The innate and adaptive immune response against 
the TPs is usually disadvantageous, as it may result in increased proteolysis and generation of 
reactive oxygen species (ROS) leading to oxidation of the TPs (Figure 1.1). However, in the case 
of proteins derived from pathogenic agents, this process is used successfully for recombinant 
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protein and sub-unit based vaccines to enhance the immune response and pharmacological action 
(20). 
 
1.1 Proteolytic enzymes in the skin, SC tissue and lymphatic system 
1.1.1 Introduction and classification of proteolytic enzymes 
The proteolytic enzymes (peptidases) are broadly categorized as endo-peptidases and exo-
peptidases based on whether they preferentially cleave the peptide backbone distant from the 
termini (Figure 1.2) or at penultimate or terminal peptides, respectively. In addition, the proteolytic 
enzymes can be classified based on the amino acid present at the catalytic site of the enzyme. The 
serine proteases, cysteine proteases, aspartic proteases, metallo-proteases are major categories 
having different catalytic sites (Figure 1.2). Detailed classification of proteolytic enzymes was 
reported elsewhere (23-26).  
 
Figure 1.2: Classification of the proteolytic enzymes or peptidases. a) Classification based on the site of their action 
on the target protein b) Classification based on the catalytic site 
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1.1.2 Proteolytic enzymes in the skin and lymphatic system 
More than 30 proteolytic enzymes are present in the skin and SC tissue. Skin has 2 major 
layers, the epidermis and dermis. In the epidermis, cysteine and serine proteases form the major 
fraction of the total proteolytic enzymes, followed by aspartic and metalloproteases (Figure 1.3) 
(27). The rat epidermis has approximately 10 times more proteolytic activity compared to the 
dermis and proteolytic enzymes are found in the epidermal cells. However, in the case of dermis, 
proteolytic enzymes were present in the infiltrating immune cells, sebaceous glands, and follicular 
cells (28).  
 
Figure 1.3: Proteolytic enzymes present in the epidermal layer of human skin 
KLK: Kallikrein-related peptidases, ADAM: A disintegrin and metalloprotease, MBTPS2: Membrane bound 
transcription factor peptidase site 2 (reproduced with permission from Veer et al (27) 
 
The skin is densely packed with various immune cells and is an immune organ itself (21). 
The cutaneous surface of normal adult humans has around 20 billion T cells, which can secrete 
proteolytic enzymes leading to degradation of the administered TPs (27, 29). The proteolytic 
enzymes such as tryptase, cathepsin G, neutrophil elastase originate from the T cells and other 
infiltrating immune cells (27). Caspase-14 is a major cysteine protease, expressed in the human 
epidermal keratinocytes. Serine protease HtrA1 is found ubiquitously in many organs; however, 
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increased amounts were found in the mature layers of the epidermis (30). Cathepsin D and E are 
found in various other organs like LNs, spleen, kidney, lung, and liver (31, 32). Cathepsin G has 
been identified in the rat spleen and LNs (33). Dipeptidyl peptidase IV (DPP-IV) was expressed 
more in the cultured human dermal lymphatic cells compared to the blood vascular endothelial 
cells (34).    
 
1.1.3 Effect of species and age on proteolytic enzymes 
Preclinical safety testing of the TPs is typically conducted in rodents, one or more large 
animals like the dog, and possibly non-human primates although these preclinical models have 
been found to poorly represent human bioavailability and PK of numerous TPs (35). Kageyama et 
al. reported that the expression of cathepsin D and E in spleen and LNs is variable across the 
species like rat, monkey and humans. The monkey spleen tissue had around 2 times higher levels 
of cathepsin D compared to the rats. In the case of monkey LNs, cathepsin D was 4-fold higher 
than the rat LNs. In contrast, the rat spleen had around 40-fold higher expression of cathepsin E 
compared to the monkey spleen. The rat LNs had around 11-fold higher cathepsin E expression 
than the monkey LNs (32). These differences in protease expression may contribute towards 
variations in overall clearance of the TPs leading to different values of bioavailability across the 
species. Further, age dependent increase in elastase like endopeptidase activity was seen in the 
mouse skin. This increase in peptidase activity is important during 6 to 15 months of the lifetime 




1.1.4 Altered expression and role of proteolytic enzymes in the pathological conditions 
Table 1.1: Proteolytic enzymes altered due to various pathological conditions 
(Adapted/modified from Veer at al (27) with permission) 
Pathological 
condition Proteolytic enzyme 
mRNA or protein 
content or 
activity of the 
peptidase(s) 
compared to the 
healthy condition 
Organ or 




syndrome Cathepsin C 
Approximately 
85% reduction in 
the enzyme 
activity, possibly 








Cathepsin B, H, L, S 
(cysteine proteases) 
Increased 






Matriptase (a serine 
protease) 
Mutation leading 
to loss of function Skin 
Basel-
Vanagaite 
et al. (39) 
Inflammatory skin 
and bowel disease Metalloprotease 17 
Mutation leading 

























Titeux et al. 
(42) 




































#Tryptase (a serine 
protease) 
Higher levels in 
the skin blister 
fluid 




*Increased DPP-IV levels in serum were correlated with enlargement of the LNs. MRL-lpr mice were used as 
a disease model for lymphadenopathy 
#Higher tryptase levels compared to the blister fluids obtained from insect bite reactions, erysipelas, burns, 
toxic epidermal necrolysis 
(DPP-IV: Dipeptidyl peptidase-IV, LNs: Lymph nodes) 
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Expression of proteolytic enzymes in the skin and SC tissue is altered during various 
diseases (Table 1.1) (27, 47). Papillon-Lefèvre syndrome (PLS) is associated with periodontitis 
and thickening of epidermis (27). Lysosomal cysteine proteases such as cathepsins-B, -H, -L and 
-S are overexpressed in the tumor cells of Morbus Hodgkin’s lymphoma. Expression of the 
cysteine proteases is increased with increasing malignancy of the lymphoma (38). Ichthyosis 
hypotrichosis syndrome of skin leads to loss of function of matriptase (a serine protease) (39). In 
the case of inflammatory skin and bowel disease, metalloprotease 17 was not expressed (40). In 
another example, epilysin or matrix metalloprotease-28, which is expressed in the skin 
keratinocytes, was induced after injury to the epidermis, because it is involved in the wound 
healing process. It degrades the adhesive proteins like cadherins or collagen to release new cells 
and thus inducing the repair mechanism (41). Epilysin expression was also increased in the 
cartilage and synovium of the patients with osteoarthritis (48). Furthermore, expression of 
matrixmetallprotease 1 was increased in the recessive dystrophic epidermolysis bullosa (42). 
The LNs were abnormally enlarged in the mouse model of lymphadenopathy. In addition, 
the serum DPP-IV levels increased in the enlarged LNs, and the levels were directly proportional 
to the weight of the LNs (43). Arg-, Ala-, and Leu-N-aminopeptidases and DPP-IV were found on 
the surface of human dermal fibroblasts. These enzymes were elevated in the human fibroblasts 
obtained from the psoriasis and rheumatoid arthritis patients. Leu-N-aminopeptidases and Arg-N-
aminopeptidases were elevated up to 1.5- to 6.6-fold, respectively compared to the healthy 
fibroblasts. While, DPP-IV was elevated by 4.5-fold compared to the healthy fibroblasts (44).  
Caspase-14 is a predominant caspase in the human stratum corneum. The immature 
pakeratotic skin from psoriasis and seborrheic dermatitis patients contained inactive procaspase-
14 along with the active caspase-14 form. In contrast, the healthy skin contained only the active 
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form, i.e. caspase-14. This study shows that proteolytic activity and expression can be significantly 
different for the healthy and diseased skin (45). Tryptase is a serine protease abundantly present 
in the mast cells of the skin. The skin blister fluid from the allergic contact dermatitis and bullous 
pemphigoid patients contained higher levels of tryptase compared to the other skin conditions like 
insect bite reactions, erysipelas, burns, and toxic epidermal necrolysis. The higher level of tryptase 
denotes that the mast cell degranulation was the pathophysiological mechanism of allergic contact 
dermatitis and bullous pemphigoid (46, 49). In addition, the UVA exposure to the mouse skin 
showed greater increase (+90 to 122%) in peptidase activity compared to the UVB exposure 
(+72%). The serine endopeptidases and metalloprotease enzymes were affected by the UVA 
radiation (36). In another study, it was found that UVB exposure increased secretion of matrix 
metalloprotease-2 by human dermal fibroblasts (50). 
 
1.1.5 Targeting disease using the protease enzymes 
Protease enzymes present in the skin, SC and lymphatic tissues may be important for 
targeting specific cell population or tumors. For example, the protease enzyme tryptase is abundant 
only in the mast cells and not in the other white blood cells like peripheral blood leukocytes and 
basophils, which have either none or very small amount of tryptase (49, 51). The solid tumors of 
epithelial origin are known to express various peptidases like urokinase, matriptase, and legumain. 
This physiological phenomenon was used to engineer a pro-mAb, which was masked with a 
peptide attached to the light chain of the mAb via a linker peptide. The linker peptide was a 
substrate of the tumor specific protease. The masked pro-mAb was inactive and the masking 
peptide was cleaved by the specific protease expressed abundantly in the cancerous cells. This 
approach of using pro-mAb was proposed to reduce toxicity and improve therapeutic index of 
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EGFR targeting mAbs used to treat head and neck squamous cell cancer, non-small cell lung 
cancer, and breast cancer (52).  
 
Key points and unknowns 
Protease enzymes play a crucial role in clearance of the TPs and they are altered in various 
animal species, with different age and disease conditions. The increased or decreased protease 
activity in the skin, SC tissue and lymphatic system may lead to differences in PK of the TPs. 
However, impact of the altered expression of protease enzymes on PK of TPs is not clearly known. 
It is important to identify the proteolytic enzymes responsible for the reduced bioavailability of 
TPs because the reduced SC bioavailability of TPs may be mitigated by co-administration of 
peptidase inhibitors. For example, an ointment of peptidase inhibitors (nafamostat or gabexate) 
was applied before the SC administration. The peptidase inhibitors penetrated the injection site 
and decreased the TP degradation in the SC tissue (53). This strategy was also used for oral and 
pulmonary delivery of proteins and peptides (54, 55).  
 
1.2. In vitro methods to study proteolysis of TPs 
Various in vitro systems (whole blood, serum, plasma, liver and kidney homogenates), 
have been used to study proteolysis of the TPs (56). The tissue homogenates and recombinant 
enzymes are most commonly used tool to evaluate stability of the TPs. The metabolism of small 
molecule drugs (SMDs) in the liver and other organs has been extensively studied using in vitro 
systems to obtain quantitative data (e.g. Chapter 4) (57). Similar information about metabolic 
processes of the TPs in the SC injection site and lymphatic system is necessary and remains to be 
generated (2, 58-61). In this section, examples and applications of the in vitro methods used to 
study degradation of TPs are discussed. 
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1.2.1 Bioavailability of TPs after SC administration 
The recombinant peptidase enzymes (e.g. DPP-IV and neutral endopeptidase), tissue 
homogenates and tissue fractions like human liver S9 fraction were used to study proteolysis of 
the TPs (62). Higher rate of the in vitro proteolysis generally indicates that the TP has lower 
bioavailability. For example, leuprolide acetate had low bioavailability of around 32% after SC 
administration. The in vitro incubation of leuprolide acetate with a rat skin homogenate lead to 
around 90% degradation of the peptide within 120 min. This may indicate that the skin is mainly 
responsible for the proteolysis (63). 
Erythropoietin is a TP with about 20-30% SC bioavailability in humans and 30-38% in rats 
(13, 64). Wang et al. used rat SC tissue homogenate and LN cell suspension to study degradation 
of erythropoietin. The incubation of erythropoietin with the SC tissue homogenate and LN cell 
suspension resulted in appearance of smaller fragments of the TP and decreased intensity of the 
parent erythropoietin after 24 h as shown by the SDS-PAGE analysis. This indicated that the 
reduced bioavailability of erythropoietin was probably due to proteolysis in the SC tissue and LNs 
(13). In another study, after SC injection to a lymph duct cannulated sheep, 61% of the hGH was 
collected in the peripheral lymph, while around 8% was collected in the central lymph. This shows 
that the hGH degraded significantly in the lymphatic system after SC administration to sheep. 
Total recovery of hGH by the lymphatic system was around 93%, indicating minimal contribution 
of SC injection site in the proteolysis (65).  
The in vitro tools composed of various cellular fractions were used to study proteolysis of 
the TPs. Microsomal, nuclear and mitochondrial fractions were prepared using rat LNs and 
incubated with the peptidase substrates- benzoyl-L-arginamide (BAA) and glycyl-L-tyrosinamide 
acetate (GTAA). The mitochondrial fraction showed highest proteolytic activity (66). Detailed 
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information about mitochondrial proteases and their classification based on function and location 
can be found elsewhere (67). 
Kinnunen et al. reported a novel in vitro platform simulating the SC injection site. The 
platform consists of a dialysis based SC injection chamber, which can be filled with multiple non-
cellular SC tissue components like hyaluronic acid. The physiological buffers were used to 
simulate the SC tissue pH conditions. Another chamber with a physiological buffer served as an 
infinite sink representing rest of the body. However, this system did not utilize proteolytic enzymes 
or cellular components responsible for proteolysis of the TPs. The platform may be used to predict 
behavior of the TP formulations, and to measure rate of release of the TPs from the SC injection 
site (68).    
 
1.2.2 Use of in vitro methods in TP engineering 
Wroblewski et al. used in vitro methodology to demonstrate that, decoy receptor 3 was 
proteolytically cleaved between amino acids 218 and 219. This information was used to improve 
the TP stability, by replacing Arg-218 with a glutamine. The modification resulted in reduced 
proteolytic degradation and increased stability of the TP (69). In another report, DPP-IV and 
neutral endopeptidase were used to find degradation products of human glucagon like peptide-1 
(GLP-1) and its modified analogue, liraglutide. Liraglutide degraded into a single metabolite in 
the presence of DPP-IV, while multiple peptides were formed after incubation with neutral 
peptidase. Rate of liraglutide degradation was slower compared to GLP-1, while, the cleavage site 
for liraglutide was similar to that of GLP-1. This study helped to understand comparative stability 




1.2.3 Proteolysis for release of small molecule drugs from ADCs 
Proteolysis of the TPs usually results in reduced bioavailability after SC administration; 
however, proteolysis is occasionally important for TPs like antibody-drug conjugates (ADCs). 
ADCs are proteolyzed and the conjugated SMD is released. The human liver S9 fraction was used 
to monitor release of the SMD and proteolysis of the TP (70). Anti-cancer drug, 
monomethylauristatin E (MMAE) was attached to cAC10 mAb via novel valine-citrulline p-
aminobenzylcarbamate (val-cit-PABC) linker. The linker was cleaved by the protease enzyme 
cathepsin B, to release MMAE (Figure 1.4). However, even without the cleavable linker, anti-
cancer drugs can be released by the non-selective proteolysis and lysosomal degradation (70, 71). 
Ado-trastuzumab (Kadcyla) is an ADC approved by the FDA that uses noncleavable linker (72). 
In addition, an ADC conjugated with monomethylauristatin F (MMAF) using a noncleavable 
maleimidocaproyl linker was equally potent compared to an ADC linked with the cleavable val-
cit-PABC linker (73). The in vitro assays can be useful to monitor release of SMDs from both the 
cleavable and non-cleavable linkers. 
 




Key points and unknowns 
The in vitro methods are used effectively to study proteolysis of the TPs, but rare to date 
provide quantitative proteolysis information. Therefore, bioavailability cannot be mechanistically 
estimated using the available in vitro systems (61). The quantitative data can be used to define the 
rate of metabolism from the SC injection sites and the lymphatic system. In addition, the data may 
be used to develop a PBPK model for PK predictions. 
 
1.3 Factors affecting PK of TPs after SC administration and PBPK modeling 
1.3.1 Effect of molecular weight on lymphatic uptake of TPs 
After SC administration the TP usually travels through the lymphatic vessels and LNs 
before it reaches the systemic circulation (74). The uptake of TPs via lymphatic capillaries after 
SC administration is dependent on its molecular weight. The TPs greater than 16 kDa molecular 
weight are generally absorbed via lymph vessels (15). Supersaxo et al. reported correlation of 
molecular weight and percent dose recovered in the lymph fluid of sheep after SC administration. 
A linear relationship was observed between percent dose recovered in the lymph and the molecular 
weight (Figure 1.5). rIFN alpha-2a (19 kDa) had percent lymphatic recovery of approximately 
60% (11). In another study, hGH (22 kDa) had lymphatic recovery of around 62% in a sheep model 
(65). Both of these studies indicate that molecular weight is important factor for the lymphatic 
transport and to understand disposition of the TPs after SC administration. 
 
1.3.2 Effect of animal species on PK of TPs 
The PK of TPs may be variable in different animal species (75). A minipig animal model may be 




Figure 1.5: Effect of molecular weight on % lymphatic recovery of various proteins after SC administration to 
sheep. 
These data were originally reported by Supersaxo et al. (11) and Charman et al. (65) The lymph was collected from 
the right popliteal lymph node of a sheep after SC administration of the protein on lower side of the right hind leg.  
(Reproduced with permission from a review article by Porter et al. (3)) 
 
similar skin structure and lymphatic plexus. Thicknesses of the epidermis and stratus corneum, 
and lipid contents of the stratum corneum are similar in humans and minipigs. In addition, the 
thickness of the SC tissue is also similar. However, the absorption rate of TPs from the SC injection 
site was 2 to 5-fold higher in minipigs compared to humans. In addition, the bioavailability of 
adalimumab was different in minipig and humans (Table 1.2) (2, 76). Hence, mechanistic 
understanding of proteolysis and absorption processes in the SC tissue of each species is important.  
 
1.3.3 Effect of the injection site on PK of TPs 
The SC injection site may be partially responsible for the proteolysis of TPs by secreting 
proteolytic enzymes in the extracellular matrix as well as by intracellular proteolysis. According 
to the published studies, hGH and insulin were degraded at the injection site (77, 78). Further, the 
bioavailability of hGH in humans was higher when injected in the abdomen compared to the thigh 
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(79). The bioavailability of insulin was different after SC injection at various injection sites 
(abdomen, thigh, and arms) (Table 1.2). The rate of absorption (indicated by Tmax) was higher for 
abdominal injection (63 min) compared to the arm (76 min) and thigh (92 min) (80). In another 
study, bioavailability of mepolizumab was 64, 75, 71 and 81% after SC abdomen, SC arm, SC 
thigh and intramuscular (IM) administration, respectively (81). The bioavailability of rituximab 
(10 mg/kg) in rats was greater after abdominal SC injection (44%), while it was lower (31%) after 
SC injection in the back. The higher SC dose (40 mg/kg) of rituximab in the back lead to 
bioavailability of 18%. This indicates saturation of FcRn-mediated protection from proteolysis (5). 
Table 1.2: Bioavailability, Tmax, and Cmax of various TPs and their relationship with the injection site, population, 
species or external conditions 
TP PK Parameter Route 
Injection site 
(Condition/Species) Reference 
 Bioavailability (%)    
Mepolizumab 64 SC Abdomen (Human) 
Ortega et 
al. (81) 
Mepolizumab 75 SC Arm (Human) 
Mepolizumab 71 SC Thigh (Human) 
Mepolizumab 81 IM NA (Human) 
Rituximab 44 SC Abdomen (Rat-10 mg/kg) Kagan et 
al. (5) Rituximab 31 SC Back (Rat-10 mg/kg) Rituximab 18 SC Back (Rat-40 mg/kg) 
Adalimumab 64 SC NA (Human) Zheng et 
al. (76) Adalimumab 83 SC Inguinal (Minipig) 
Darbepoetin alpha 106 SC Interdigital (Sheep) Kota et al. 
(12) Darbepoetin alpha 85 SC Abdomen (Sheep) Darbepoetin alpha 92 SC Shoulder (Sheep) 
 Tmax (min)    
Insulin 92 SC Thigh (Human) 
Berger et 
al. (80) 
Insulin 76 SC Arm (Human) 
Insulin 63 SC Abdomen (Human) 
Insulin 30 SC Thigh (Hot water bath- Human) 
Insulin 135 SC Thigh (Cold bath- Human) 
Insulin 38 SC Thigh (Local massage) 
Insulin lispro 60 SC Abdomen (Normal weight-Human) de la Peña et al. (82) 
Insulin lispro 90 SC Abdomen (Obese Human) 
 Tmax (h)    
Darbepoetin alpha 6-8 SC Interdigital (Sheep) Kota et al. 
(12) Darbepoetin alpha 18-72 SC Abdomen (Sheep) Darbepoetin alpha 6-12 SC Shoulder (Sheep) 
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 Cmax (pmol/L)    
Insulin lispro 822 SC Abdomen (Healthy normal weight-Human) de la Peña et al. (82) Insulin lispro 560 SC Abdomen (Obese Human) 
 
The rate of absorption of darbepoetin alpha was different for various SC injection sites like 
interdigital space, abdomen and shoulder. Tmax for interdigital space, abdomen and shoulder was 
6-8, 18-72, and 6-12 h., respectively. These differences may be attributed to alterations in the 
lymphatic vasculature and characteristics of the SC tissue at various injection sites. In addition, 
the authors reported that for the SC injection via interdigital space, the lymphatic pathway was a 
major absorption route (around 90%). While in the case of abdominal SC injection, the lymphatic 
absorption was around 67% (12).  
The studies described above indicate that injection site is an important factor governing 
bioavailability of the TPs. Change in the bioavailability with different injection sites may be due 
to differences in the proteolytic degradation in the SC tissue and lymphatic system or variation in 
the uptake of the TP by lymphatic plexus. A few reports showed that bioavailability, and PK profile 
of the TP was similar when various injection sites such as abdomen, arm and thigh were compared 
(83, 84). Nonetheless, SC injection site and the lymphatic system are important for proteolysis of 
the TPs and can impact their bioavailability and other PK parameters. 
 
1.3.4 Physiological factors responsible for absorption and proteolysis of TPs 
The physiological factors related to the SC injection site are important to govern the 
transport of TPs. For example, obese rats had a bioavailability of around 19%, while normal rats 
had a bioavailability of around 45% after SC administration of PEGylated erythropoietin. The 
lymphatic uptake in the fatty/adipose tissue may be reduced leading to low bioavailability. The 
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proteolytic activity may also change due to the fat content; however, this remains to be investigated 
further. Higher body weight was associated with lower SC bioavailability in humans (13) and the 
SC tissue thickness was correlated with the body mass index (BMI). In general, the thickness 
increased with increasing BMI, and females had higher thickness as compared to males (Figure 
1.6) (85). These differences in the SC tissue thickness may lead to altered rate and extent of the 
absorption. Injection depth relative to the underlying muscle layer will vary with the SC tissue 
thickness, but it has been shown that the PK of insulin lispro was independent of the injection 
depth in normal and obese patients (82). In addition, it can be speculated that the body weight and 
SC tissue thickness are positively correlated with each other. Therefore, it needs to be examined 
further if reduced bioavailability due to increased body weight was in fact due to increased SC 
tissue thickness. In another study, it was reported that obese mice had significantly lower 
lymphatic fluid transport (86). This alteration in the lymph flow may also change transit of the TPs 
via the lymphatic system and affect overall PK. The TPs would generally first travel through the 
initial lymphatics (lymphatic capillaries), next through the pre-collecting lymphatics and finally 
through the collecting lymphatics (lymphatic trunks) and lymphatic ducts (Chapter 2, Figure 2.2). 
Therefore, lymph flow rates and dimensions of the lymphatic vessels are important physiological 
factors responsible for lymphatic transport of the TPs (74). 
The flow rates and physiology of the lymphatic system play an important role in 
determining the PK of TPs. In a recent report by Varkhede and Forrest, lymph flows and 
physiological data related to the lymphatic system were used in a minimal PBPK model to 
understand the clinical PK of several mAbs (74). Lymphatic capillaries have diameters of around 
10 to 60 µm (human) and are connected to the lymphatic trunks via pre-collecting lymphatics (87). 
The pre-collecting lymphatics have diameters ranging from 35 to 150 µm or sometimes 300 µm 
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(measured in human thigh) (88). The lymphatic trunks have diameters of around 1-2 mm in the 
lower limbs. Lymphatic trunks originating from the right-hand side of the head, thorax and right 
arm; join the right lymphatic duct, which meets the systemic circulation in the right subclavian 
vein. The lymphatic vessels from the rest of the body (left-hand side of the head, left arm, and 
lower limbs) are connected to the thoracic duct, which meets systemic circulation at the junction 
of jugular and left subclavian veins (87). 
 
 
Figure 1.6: SC tissue (insulin injection site) thicknesses in type-2 diabetes adult patients. 
Each data point represents mean and standard deviation. BMI: Body mass index (kg/m2), Male BMI <17 (n=8), 
female BMI<17 (n=4), male BMI 17-19 (n=11), female BMI 17-19 (n=3), male BMI 19-23 (n=29), female BMI 19-
23 (n=14), male BMI 23-25 (n=11), female BMI 23-25 (n=5), male BMI >25 (n=9), female BMI >25 (n=7). 
These data were originally reported by Jain et al. (85) (Reproduced with permission). 
 
 
Figure 1.7: Cutaneous lymph flow rates in various regions of the human body 
These data were originally published by Fujiwara et al. (89) (Reproduced with permission) 
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Cutaneous lymph flow rates in melanoma patients were different in various regions of the 
body as shown in Table 1.3. Hence, absorption of TPs may differ when administered at different 
injection sites. Skin lymph flow rate in the leg and foot region were approximately 7-fold greater 
than the head and neck region (90). In another publication, mean cutaneous lymphatic transport 
rate was reported as highest in the lower limbs (4.07 ± 0.35 cm/min), followed by upper limb (2.67 
± 0.33 cm/min), trunk (1.79 ± 0.47 cm/min), and, head and neck region (1.11 ± 0.22 cm/min) 
(Figure 1.7) (89). 
Table 1.3: Cutaneous lymph flow rates in various body regions in humans 
Site Average flow (cm/min) 
Head and neck 1.5 
Anterior trunk 2.8 
Posterior trunk 3.9 
Arm and shoulder 2.0 
Forearm and hand 5.5 
Thigh 4.2 
Leg and foot 10.2 
These data were originally published by Uren RF (90) 
(Reproduced with permission). 
 
The pre-nodal lymph flow measured in the healthy human leg joint was 13.2 ± 1.1 mL/24 
h (91). In another study, average afferent lymph flow rate was 10.4 cm/min (human) (92). In the 
case of sheep, popliteal efferent lymph flow rate was 2 to 10 mL/h (93). Quin et al. also reported 
afferent (4.58 ± 0.6 mL/h) and efferent (3.87 ± 0.58 mL/h) lymph flow rate for the popliteal lymph 
node in a sheep (94). Efferent lymph flow for the iliac lymph node in rats was 66 ± 6 µL/h while 
efferent lymph flow rate from the mesenteric lymph node in rats was 132 ± 41 µL/h (95). The 
afferent lymph flow rate in dogs was 19.1 ± 0.3 µL/min (96). 
In addition, the thoracic lymph duct and right lymphatic ducts are important because most 
of the lymph generated in the body is transported through either of the two lymph ducts. The 
thoracic duct lymph flow rate is variable across various species (sheep-5.4 ± 3.1 ml/min, rat-0.038 
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ml/min) (97, 98). The thoracic duct diameter was of 3.6 ± 0.1 mm in healthy humans (99). In 
another report, the diameter was reported as a range of 2 to 5 mm. The length of the thoracic lymph 
duct is around 45 cm (100). Thoracic duct lymph flow was 0.7 to 1.6 mL/kg/h in humans (92). 
Thoracic duct lymph flow in mouse was 0.83 to 1.66 mL/h, while it was 1 to 10 mL/h (101) or 2.3 
mL/h (97) in rats. Various literature values of the thoracic lymph duct flow rates were mentioned 
by Giragossian et al. (102). Length of the thoracic lymph duct in rats is 3 to 7 cm (101). While, 
internal diameter of the rat thoracic duct was 405.5 ± 10.1 µm (103) or 0.4 to 1 mm (101). This 
variation may lead to differences in the PK across and within the species. 
It is possible that the number of LNs to which the TP is exposed, would differ after SC 
injections at various injection sites. For example, if the SC injection site was lower limb or thigh, 
the TP would travel through the inguinal and iliac LNs. If the TP was administered on the arm, it 
would pass through the axillary and bronchomediastinal trunk LNs. In both of the cases, number 
of LNs through which the TP has to pass before reaching the systemic circulation would be 
different. Due to this differential lymphatic exposure, extent of the lymphatic proteolysis would 
differ after SC injection at various injection sites (74). 
The cutaneous blood flow rates may be important for the absorption of the smaller 
molecular weight (< 22 kDa) TPs, although they have minimal effect on the larger TPs (e.g. mAbs). 
Differences in the skin blood flow may result in altered degree of TP absorption and proteolysis 
(75, 90, 104). Dermal blood flows were different in various animal species and in specific regions 
of the body such as buttocks, ear, humeroscapular joint, thoracolumbar area, and abdomen (Table 




Table 1.4: Dermal blood flow (milliliters/minute per 100 gm) in various animal species and in specific regions of the 
body 
Site Mouse Rat Dog Pig Monkey 
Buttocks 3.88±0.92 4.20±1.05 2.21±0.67 3.08±0.48 3.12±0.58 
Ear 1.41±0.48 9.13±4.97 5.21±1.53 11.7±3.02 20.93±5.37 
Humeroscapular 
area 10.10±3.51 6.22±1.47 5.52±1.31 6.75±2.09 8.49±3.28 
Thoracolumbar 
area 20.56±4.69 9.56±2.17 1.94±0.27 2.97±0.56 2.40±0.82 
Ventral abdomen 36.85±8.14 11.35±5.53 8.78±1.40 10.68±2.14 3.58±0.41 
Each value represents mean and standard error. 
These data were originally reported by Monteiro-Riviere et al. (105) (Reproduced with permission). 
 
1.3.5 Effect of the disease and exercise on the physiological parameters related to the lymphatic 
system 
The thoracic lymph flow rate was 1 mL/min in the case of patients without cirrhosis, while, 
it was 3 to 6 times higher in the cirrhosis patients (107). The thoracic lymph duct flow rate was 
also measured in pigs, and the impact of lipopolysaccharide (LPS)-induced sepsis was studied. 
Normal thoracic lymph duct flow in pigs was around 1.5 mL/min; however, the lymph flow rate 
was doubled after IV LPS administration. This increase in lymph flow was attributed to increased 
intra-abdominal pressure. LPS sepsis can also increase permeability of the lymphatic capillaries 
(108). Another study reported that the nodal lymph flow in cancer cell injected nodes was reduced 
compared to the normal nodes in rats. In the case of normal LNs, lymph flow was 1.49 ± 0.64 
ml/gm/min, while it was 0.5 ± 0.24 ml/gm/min for cancer cell injected nodes (109). The pre-nodal 
lymph flow was 13.2 ± 1.1 mL/24 h for healthy humans (measured in leg joint). However, this 
lymph flow increased to 22.6 ± 3.2 mL/24 h for rheumatoid arthritis patients (91). Thoracic duct 
has diameter of 3.6 ± 0.1 mm in healthy humans. The diameter increased (4.8 ± 0.4 mm) in the 
case of patients with portal hypertension (99). In addition, physical activity or exercise, heat, 
massage, increase in hydrostatic pressure in the lymph vessels may result in elevated lymph flow. 
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In contrast, cold, lack of movement and external pressure may lead to reduced lymph flow (75, 90, 
104). In addition, the thoracic lymph duct flow in dogs increased while they were exercising. 
Normal thoracic duct lymph flow was 1.7 mL/min, while, during the exercise (1.5 miles/h on a 
treadmill), the lymph flow increased by 121% (3.9 mL/min). Further increase in the treadmill 
speed (10 miles/h) increased the lymph flow by 419% (9 mL/min) (110). In a PK evaluation, the 
hot water bath and massage elevated the serum insulin levels, while, the cold water bath delayed 
the absorption (Table 1.2) (80). Overall, the disease states and exercise can alter various lymph 
flows, which may lead to changes in the PK.   
 
1.3.6 PBPK model for TPs after SC administration 
The PBPK models are useful for PK prediction and estimation of the first in human dose 
for the new chemical entities (TPs and SMDs). The in vitro clearance data (e.g. liver microsomes) 
is used extensively in the PBPK models of SMDs (Chapter 4) (111). However, this strategy has 
not been used extensively for the TPs. Hence, the in vitro proteolysis data generated using SC 
tissue and lymphatic system may be important for prediction of PK of the TPs using the PBPK 
model. Giragossian et al. used the serum in vitro stability data of the TP in a PBPK model for PK 
prediction (102). In the Chapter 2 of this dissertation, the minimal PBPK model (Figure 2.1) was 
used to understand mAb transport in the lymphatic system and to identify physiological and 
physicochemical factors governing the absorption after SC administration (74). The model 
described a step-by-step transfer of TPs from the SC interstitial space towards the systemic 
circulation via lymphatic capillaries, lymphatic trunks, LNs and thoracic duct. We hypothesized 
that, the TPs are proteolyzed during the lymphatic transit, especially in the LNs. Unfortunately, 
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the in vitro data to describe rate of clearance from the LNs was not available, hence a top-down 
approach was used with parameter estimation using clinical SC PK data. 
 
Key points and unknowns 
The physiological parameters related to the lymphatic system are important for transport 
of TPs from the SC injection site towards the systemic circulation. These parameters may be 
altered due to the disease conditions. In addition, the physiological parameters are different across 
various species, which can lead to differences in the PK and bioavailability. The in vitro systems 
representing the SC and lymphatic tissues can be utilized to generate quantitative proteolysis 
information. The LN cell suspension may be an appropriate system to account for the proteolysis 
in the LNs. Finally, the PBPK model can be constructed using the physiological parameters and in 
vitro proteolysis data to understand and predict PK of the TPs. 
 
1.4 Conclusions and Specific Aims 
Incomplete bioavailability is a major disadvantage for the TPs administered via SC route. 
However, mechanism of proteolysis of the TPs in the SC tissue and lymphatic system is not 
completely known. In the case of SMDs, a bottom up approach is commonly used for PK 
prediction (Chapter 4). However, this approach has not been utilized widely for TPs. The PBPK 
model proposed in this dissertation (Chapter 2) can be applied to include the in vitro clearance data 
for the bottom up PK prediction of mAbs. In addition, oxidation is another metabolic process 
which can potentially alter PK of the TPs. The ROS present in the SC tissue and lymphatic system 
can oxidize the TP. Furthermore, the iron shredded by the injection needle may oxidize the 




Specific Aim of the Chapter 2: a) To understand the absorption of mAbs via lymphatic 
system after SC administration using the minimal PBPK model, and b) to demonstrate application 
of the model for prediction of SC PK of mAbs  
 
Specific Aim of the Chapter 3: a) To evaluate the impact of iron oxide nanoparticles 
(IONPs) on hydrogen peroxide (H2O2)- and 2, 2′-azobis (2-methylpropionamidine) 
dihydrochloride (AAPH)-mediated oxidation of a model protein, rat growth hormone (rGH), and 
b) To measure the effect of IONPs on the secondary structure of rGH 
 
Specific Aim of the Chapter 4: To investigate influence of inflammation on the metabolism 
and PK of midazolam (MDZ) and construct a minimal PBPK model to predict its PK in mice with 
inflammatory disease   
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Chapter 2 : Understanding the monoclonal antibody disposition after subcutaneous 
administration using a minimal physiologically based pharmacokinetic model 
2.1 Introduction 
Monoclonal antibodies (mAbs) are an important class of therapeutic proteins (TPs) 
administered mainly via the subcutaneous (SC) route due to shorter clinical visits for patients, the 
possibility of self-administration, and its less invasive nature. However, when compared to the 
intravenous (IV) route, SC injection has challenges associated with the incomplete bioavailability 
and pain-free administration of larger fluid volumes (1). The SC tissue and lymphatic system are 
important barriers for the absorption of mAbs. After SC administration, the mAbs travel through 
the lymphatic vessels and lymph nodes before reaching the systemic circulation. The SC 
bioavailability of mAbs is typically in the range of 52 to 80% (2, 3). Proteolysis within the 
lymphatic system and the SC injection site may be partially responsible for the reduced 
bioavailability of mAbs. The rate of neonatal Fc receptor (FcRn) binding and recycling exceeds 
the rate of lysosomal/endosomal trafficking of mAbs; therefore, endosomal proteolysis may 
contribute only minimally to low mAb bioavailability (3, 4). In addition, the target mediated drug 
disposition (TMDD) is often saturated due to limited receptors. Thus, mAbs are cleared slowly 
from the systemic circulation. The TPs like IgG1, IgG2 and IgG4 have a long half-life of around 
23 days (3), which is substantially longer than other proteins of similar molecular weights. Further, 
the appearance rate of mAbs in the plasma is slow (Tmax generally 2-14 days) (3). The low 
bioavailability of mAbs may result from efficient pre-systemic clearance mechanisms or 
irreversible retention (and subsequent elimination) of significant dose at the injection site or in the 
surrounding tissues.  
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Charman et al. investigated the causes of reduced bioavailability of human growth hormone 
(hGH) protein using a sheep model. The SC injection site degradation was minimal for hGH, while 
the lymphatic proteolysis was mainly responsible for its reduced bioavailability after SC 
administration (5). We hypothesize that the interstitial proteolysis in the lymphatic system may be 
responsible for lower bioavailability of mAbs after SC administration. In this study, a minimal 
physiologically based pharmacokinetic (PBPK) model was used to understand the sequential 
transit of mAbs and to estimate lymphatic clearance using the SC pharmacokinetics (PK). The 
model was constructed using physiological parameters related to the SC injection site, lymphatic 
system and the reported clinical IV PK data. This study had the following major objectives: a) 
construction of the minimal PBPK model focusing on the lymphatic transit of mAbs after SC 
administration using physiologically relevant lymph flows and compartment volumes, b) 
estimation of the lymphatic clearance using literature SC PK data, and c) identification of the 
parameters governing the absorption of mAbs via the SC and lymphatic system.  
Various PBPK models for TPs have been reported recently and as early as 1995 (Gill et 
al., Abbuqayyas and Balthasar, Garg and Balthasar, Baxter et al., Shah and Betts) (6-9). Some of 
the authors (Zhao et al., Chen et al., Elmeliegy et al., Li et al.) proposed the minimal PBPK 
approach to eliminate complexity associated with the models (3, 10-12). Although, these models 
may be useful for a mechanistic understanding of the clearance and absorption processes at the SC 
injection site and in the lymphatic system, use of PBPK modeling for TP PK prediction is limited 
(13). After SC injection, the mAb travels through the lymphatic capillary network, lymph nodes, 
lymphatic trunks and thoracic lymph duct before joining the systemic circulation. Hence, in this 
study, the lymphatic organs were incorporated in the minimal PBPK model, and the lymphatic 
trunk-lymph node (LN) clearance was estimated using the SC PK. Interestingly, it appears that the 
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estimated lymphatic trunk-LN clearance was directly proportional to the isoelectric point (pI) of 
the mAb. In addition, the model must be combined in the future with in vitro proteolysis data 
obtained from the lymphatic system to predict SC PK and bioavailability of mAbs. Further, the 
variability in the PK due to different populations, disease conditions, formulations, novel delivery 
technologies, and biophysical properties of the TP may be addressed using the minimal PBPK 
model (14). Overall, the proposed minimal PBPK model can be used for mechanistic 
understanding of mAb absorption and prediction of PK after SC administration. 
 
2.2 Methods 
2.2.1 Digitization of literature IV and SC PK data  
The IV (35 profiles) and SC (37 profiles) PK of 10 mAbs were obtained from literature 
and digitized using WebPlotDigitizer (version 4.1) (15). This web-based tool has been extensively 
used in other reports (16). The IV PK profiles were used to estimate 2-compartment model 
parameters, while the SC PK profiles were used to estimate the lymphatic trunk-LN clearance.   
 
2.2.2 Construction of the minimal PBPK model 
The minimal PBPK model was constructed using SimBiology (Matlab R2017a). The 
physiologically based model and simple compartmental model were combined to describe 
absorption of mAbs after SC administration (Figure 2.1). The model equations describing FcRn 
binding and transfer across interstitial, endosomal and vascular space were adopted from 
previously reported studies (3, 9, 17). However, additional physiological parameters related to the 
lymphatic system were either calculated or obtained from the literature (Table 2.1) and used to 
construct the model. The model parameters specific to mAbs are listed in Table 2.2. Furthermore, 
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additional compartments were included to describe the sequential transfer of mAbs through the 
lymphatic system. It was assumed that the SC dose of mAb distributes equally in the SC interstitial 
space after the injection. 
 
Figure 2.1: Schematic representation of the minimal PBPK model for mAb absorption after SC injection 
 
 




2.2.3 Physiological parameters related to the SC injection site and lymphatic system 
The physiological parameters related to the SC injection site and lymphatic system were 
either obtained or calculated from the literature (Table 2.1). The SC injection site volume was 
calculated by Gill et al. (9) using the diameter of the SC injection depot of radiolabeled IgG.  
While, the SC site lymph flow was measured using the rate of radiolabeled IgG loss from a SC 
administration site (9). Lymphatic capillary volume was calculated using the average distance 
between the injection site and sentinel LN (30 cm), the lymphatic network density per 1 cm annulus 
of arm skin (385 cm), and the average radius of lymphatic capillaries (0.0274 mm) (18-20). 
Afferent lymph flow was calculated using the reported lymphatic flow rate (40 mm/min) and 
radius (0.0274 mm) of the lymphatic capillaries in humans (21, 22). The efferent lymph flow rate 
in sheep was used in the model (23). The volume of the lymphatic trunk was calculated based on 
an approximate length of 30 cm and a radius of 1 mm (20). 
The total LN volume was calculated based on the number of LNs (45 to 50) to which the 
mAb is exposed after SC injection in thigh (24-26). The average volume of cervical LNs (0.292 
mL) reported in humans was used to calculate the total LN volume after SC injection in the upper 
arm, abdomen, and thigh (27). The SC injection of a TP in thigh would lead to its travel through 
the inguinal, iliac and lumbar LNs (Figure 2.2). Upon SC injection in the upper arm, the TP would 
travel through the cubital and axillary LNs followed by the subclavian trunk. After passing through 
the LNs and lymphatic trunks, TPs would join the central lymphatic system (thoracic duct and 
cysterna chyli), which are lymphatic vessels with greater diameters. The TP would join the 
systemic circulation via the thoracic duct if the SC injection site were left upper arm, whereas 
injections into the right upper arm, would enter either via the right thoracic duct or thoracic lymph 
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duct (Figure 2.3). After abdominal SC injection, the TP would generally travel via inguinal, iliac, 
and lumbar LNs towards the cisterna chyli and thoracic duct, to enter the systemic blood circulation 
via the subclavian vein. The known anatomical structure of lymphatic system was utilized to define 
the sequential transfer of mAbs (24-27). 
 
Figure 2.3: Sequential transfer of mAbs towards the systemic circulation after SC injection in, A) Thigh, B) 
Abdomen, and C) Upper Arm 
The lymphatic trunk and LN volumes were combined to calculate the interstitial lymphatic 
trunk-LN volume. The total endosomal volume of LNs was calculated based on the endosomal 
volume in a peripheral mononuclear cell (28) and the number of lymphocytes in a LN (29). The 
endosomal LN volume and the combined lymphatic trunk-LN interstitial volume for various SC 
injection sites (thigh, abdomen, and upper arm) were approximately similar (Table 2.1).  
The central lymphatic system’s volume was dependent on the site of SC injection. In the 
case of SC injection to the thigh, abdomen or left upper arm, the TP would travel through the 
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thoracic lymph duct. In the case of thigh and abdominal injections, volume of the cisterna chyli 
should be included in the central lymphatic volume. For this model, it was assumed that the SC 
injection site was either thigh or abdomen, therefore, the volume of the thoracic duct and cisterna 
chyli were included in the central lymphatic volume. However, the volume of the central lymphatic 
system after injection in an upper arm or thigh was found to be similar, because the volume of the 
cisterna chyli was negligible as compared to the thoracic duct volume (Table 2.1). Volumes of the 
thoracic lymph duct and cisterna chyli were calculated based on literature values of length and 
diameter. In the case of the thoracic lymph duct, the length and diameter were 45 and 5 cm, 
respectively. While, in the case of cisterna chyli, the length and diameter were 2-5 mm and 1 cm, 
respectively (30). 
Table 2.1: Human physiological parameters related to the SC injection site and lymphatic system 
Parameter Value Reference 
𝑉"#$  (SC injection site interstitial volume) 0.003115 L (9) 
𝑉"#%  (SC injection site endosomal volume) 0.000025 L (9) 
𝑉"#&  (SC injection site vascular volume) 0.00025 L (9) 
𝑉'#() (Volume of the lymphatic capillaries) 0.00033 L Calculated (18-20) 
𝑉'*+,-$  (Combined interstitial volume of lymphatic 
trunk and LNs after SC injection in upper arm)a 
0.01408 L Calculated (24-27) 
𝑉'*$  (Combined interstitial volume of lymphatic trunk 
and LNs after SC injection in thigh) 
0.01349 L Calculated (25-27, 
31) 
𝑉'*+-.$  (Combined interstitial volume of lymphatic 
trunk and LNs after SC injection in abdomen)a 
0.01758 L Calculated (25-27, 
32) 
𝑉'*+,-%  (Combined endosomal volume of all LNs to 
which the mAb is exposed after SC injection in upper 
arm)a 
0.000014 mL Calculated (24-29) 
𝑉'*%  (Combined endosomal volume of all LNs to 
which the mAb is exposed after SC injection in 
thigh) 
0.0000126 mL Calculated (28, 29, 
31) 
𝑉'*+-.%  (Combined endosomal volume of all LNs to 
which the mAb is exposed after SC injection in 
abdomen) 
0.00001596 mL Calculated (25-29, 
32) 
𝑉'*+#/0 (Volume of central lymphatic system) 0.00888 L Calculated (30) 
𝑉1234 (Volume of thoracic lymph duct)
b 0.00884 L Calculated (30) 
𝑉##  (Volume of cisterna chyli)
b 0.000039 L Calculated (30) 
𝐿"#  (Lymph flow at the SC injection site) 0.0001356 L/h  (9) 
𝐿-66 (Lymph flow afferent to LNs in human) 0.00000564 L/h Calculated (21, 22) 
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𝐿%66 (Lymph flow efferent to LNs in sheep) 0.00387 L/h (23) 
𝐿1234 (Thoracic duct lymph flow rate) 0.06 L/h (33, 34) 
𝑄"#  (Blood flow at the SC injection site) 0.04992 L/h  (9) 
𝐶%093 (Concentration of endogenous mAb in 
endosomal compartment) 
10000 mg/L (3) 
𝐾𝑑 (Dissociation constant for antibody FcRn 
binding) 
45.36 mg/L (35) 
𝑛𝑃𝑡 (FcRn concentration in SC tissue or LNs) 2880 mg/L (36) 
aNot used in the model (SC injection site was assumed as thigh) 
bUsed to calculate total central lymphatic volume 
 
Table 2.2: mAb related parameters used in the minimal PBPK model 
Parameter Value Reference 
s& (Vascular reflection coefficient) 0.95 (3, 17) 
s' (Lymphatic reflection coefficient) 0.2 (3, 17) 
𝑅1 (Endosomal uptake rate of antibody) 0.00000926 /h (3, 4) 
𝑅2 (Endosomal return rate of antibody) 0.26 /h (3, 4) 
𝐹𝑅 (Recycling fraction of FcRn bound mAb) 0.715 (3) 
𝐶𝐿%093+"#  (Endosomal clearance of mAb in SC injection 
site)a 
0.003675 L/h (17) 
𝐶𝐿%093+'* (Endosomal clearance of antibody in LNs)
b 0.0001254 L/h (17) 
aEndosomal clearance in skin assumed to be similar to SC injection site 
bEndosomal clearance in spleen assumed to be similar to lymphatic trunk-LN 
 
2.2.4 Parameter estimation and sensitivity analysis 
A nonlinear mixed-effects model with stochastic EM algorithm was used for estimation of 
the 2-compatmental IV PK parameters. The lymphatic trunk-LN clearance was estimated using 
either the nonlinear mixed-effects model with stochastic EM algorithm or a nonlinear least squares 
solver. Sensitivity analysis was performed on the physiological, mAb related and estimated 
parameters (Figure 2.9 S1 and Figure 2.10 S2). The parameters were altered by 0.1-, 0.3-, 0.5-, 
0.7-, 1-, 3-, 5-, 7-, 10-, 50- and 100-fold of the original values as mentioned in Table 2.1. The 
lymphatic reflection coefficient was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 1.5-, 2-, 2.5-, 3-, 3.5-, 4-, 




2.2.5 Model validation 
The model was validated by comparing observed and predicted PK profiles after SC 
administration. In addition, accuracy of the predictions was assessed by plotting ratios of Tmax-
observed/Tmax-predicted, Cmax-observed/Cmax-predicted with the pI, lymphatic trunk-LN clearance, and 
bioavailability (Figure 2.11 S3, Figure 2.12 S4 and Figure 2.13 S5). The bioavailability and pI 
values for mAbs were obtained from the literature (37-50). In the case of anifrolumab, the pI value 
was estimated using the amino acid sequence (51) and ProtParam, a web-based tool (52). 
 
2.3 Results 
2.3.1 Estimation of the 2-compartment IV parameters 
The 2-compartment model was used to estimate the parameters using the literature PK data after 
IV bolus or infusion (Table 2.3). These parameters were different for each mAb, and they were 
fixed in the minimal PBPK model. The mAbs had average volume of 3.5571 L (standard deviation, 
± 1.1081) for the central compartment and 1.8069 L (standard deviation, ± 1.0308) for the 
peripheral compartment. Mean values for CLcen, K12 and K21 were 0.01531 L/h, 0.0992 /h and 
0.3448 /h, respectively. 
Table 2.3: The 2-compartmental model parameters for various mAbs after IV administration 
mAb Vcen (L) Vper (L) CLcen (L/h) K12 (/h) K21 (/h) Reference 
Adalimumab 3.2131 2.2382 0.01023 0.01162 0.01669 (53) 
Anifrolumab 2.1732 3.7869 0.0111 0.02024 0.01161 (54) 
Belimumab 3.0486 2.3877 0.009602 0.01635 0.0208 (43, 44) 
Canakinumab 3.2897 2.3638 0.007541 0.009417 0.0131 (40) 
Daclizumab 5.5255 1.762 0.01104 0.00257 0.00805 (55) 
Golimumab 2.3293 2.3279 0.01467 0.01302 0.01302 (42, 56) 
Guselkumab 4.9381 0.4131 0.0233 0.000871 0.0104 (46) 
Infliximab 4.5782 1.2645 0.0169 0.8914 3.2276 (57) 
Tocilizumab 3.5145 1.0064 0.03585 0.01084 0.0378 (58) 
Trastuzumab 2.9608 0.5186 0.01291 0.0157 0.0896 (59, 60) 
Mean 3.5571 1.8069 0.01531 0.0992 0.3448  
Standard 
deviation 




2.3.2 Estimation of the lymphatic trunk-LN clearance 
A single parameter (lymphatic trunk-LN clearance) was estimated and the rest of the model 
was fixed using literature values as described in the methods section. The clearance represents 
proteolysis of mAbs in the interstitial space of the lymphatic trunks and LNs (Figure 2.4). The 
model predicted a total of 37 SC PK profiles (10 mAbs with 26 different doses), which were 
compared with the mean observed published data (Figure 2.5 and Figure 2.6). However, in the 
case of belimumab, the patient-PK profile was a geometric mean. The estimated lymphatic trunk-
LN clearance was in the range of 0.0001495 to 0.007776 L/h with a mean of 0.00213 L/h 
(0.001332 to 0.002928, lower and upper 95% confidence intervals of the mean) for a total of 37 
SC PK profiles. Average lymphatic trunk-LN clearance values for each mAb are shown in Table 
2.4. 
Table 2.4: Estimation of lymphatic trunk-LN clearance after SC administration of mAbs 
mAb (SC 
injection site) SC Dose and (F) Population Ref. 





40 mg (64%) Healthy volunteers (39) 0.00192 L/h 
Anifrolumab 















200, 2*120, 240 mg 
(76%) Healthy volunteers (44) 0.00000024 L/h 
Canakinumab 
(NA) 150, 300 mg (70 %) Healthy volunteers (40) 0.001116 L/h
 
Daclizumab** 




50, 100 mg (50 %) Healthy volunteers (41, 42) 0.00651L/h 
Guselkumab 
(NA) 
10, 30, 100, 300 mg 
(49%) Healthy volunteers 
(46, 
47) 0.002389 L/h 
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162 mg (with 




482, 645, and 776 mg 









(64) 0.0004889 L/ha,d 
Trastuzumab 
(Thigh) 
600 mg (with 
hyaluronidase) Healthy volunteers (65) 0.001839 L/h
a,e 
Mean CLLN: 0.00213 L/h (Standard deviation: 0.002359, lower 95% confidence interval of the mean: 0.001332, 
upper 95% confidence interval of the mean: 0.002928 L/h) 
Nonlinear mixed-effects model with stochastic EM algorithm used for estimation of the parameters unless 
indicated. All observed SC PK data were mean values unless indicated. 
aNonlinear least squares solver 
bSC Site lymph flow (0.04474 L/h) and CLLN estimated simultaneously 
cSC Site lymph flow (0.002798 L/h) and CLLN estimated simultaneously 
dSC Site lymph flow (0.003112 L/h) and CLLN estimated simultaneously 
eSC Site lymph flow (0.01307 L/h) and CLLN estimated simultaneously 
F: Bioavailability after SC administration 
*Geometric mean of the observed pharmacokinetic data  
**The model simulated median pharmacokinetic data 
CLLN: Clearance of mAb in the lymphatic trunk-LN interstitial compartment 
NA: Not available 
 
 
Figure 2.4: Estimated lymphatic trunk-LN clearance for a) all mAbs used in this study, b) individual mAbs (Mean 




2.3.3 Applications of the minimal PBPK model to evaluate impact of hyaluronidase in the mAb 
formulation 
The mAbs for the SC administration are formulated as highly concentrated solutions in 
order to deliver higher doses (typically 500-900 mg). The injection volume cannot be increased 
more than 1-2 mL due to injection discomfort (66). However, hyaluronidase has been used in 
several studies to allow higher injection volumes by disrupting the complex network of the SC 
extracellular matrix formed by hyaluronic acid. In addition, the hyaluronidase enzyme can increase 
the rate of TP absorption leading to decreased Tmax, increased Cmax, increased area under the curve 
(AUC), and enhanced bioavailability of the TPs (66, 67). In this study, the SC PK data obtained 
after co-formulation of hyaluronidase, and tocilizumab and trastuzumab were used to estimate the 
lymphatic trunk-LN clearance (58, 63-65). Due to the co-formulation with hyaluronidase, Tmax was 
over-predicted for tocilizumab and trastuzumab. The Observed Tmax/Predicted Tmax ratio for 
tocilizumab and trastuzumab was 0.58 and 0.6, respectively. We hypothesized that the alteration 
of SC injection site by hyaluronidase may lead to altered SC injection site lymph flow. Therefore, 
lymphatic trunk-LN clearance and SC injection site lymph flow were estimated simultaneously 
(Table 2.4). After the simultaneous estimation of both the parameters, Tmax prediction was 
improved for tocilizumab (Observed Tmax/Predicted Tmax= 0.87). Similarly, trastuzumab Tmax 
prediction accuracy was also improved (Observed Tmax/Predicted Tmax= 0.82). The estimated SC 
injection site lymph flow for the co-formulation of the mAb and hyaluronidase was higher when 
compared to the original lymph flow used in the model. The estimated SC injection site lymph 
flow for tocilizumab was 0.04474 L/h, which was 330-fold higher than the minimal PBPK model’s 
value (Table 2.1). In the case of trastuzumab, the average SC injection site lymph flow was 
45 
 
0.002955 L/h (22-fold higher than the original value) for healthy volunteers and HER2-positive 
breast cancer patients (64) (observed and model estimated PK profiles shown in Figure 2.6). In the 
case of other SC PK profile (65) (data not shown) obtained from the healthy volunteers, SC site 
lymph flow was 0.01307 L/h (96-fold higher than the original value).  
In addition to above analysis, the SC PK (tocilizumab) profiles obtained without co-
formulation with hyaluronidase enzyme were also used for simultaneous estimation of the SC 
injection site lymph flow and lymphatic trunk-LN clearance using the minimal PBPK model. This 
was done to demonstrate that the change in the SC site lymph flow observed previously was in 
fact due to co-formulation of hyaluronidase and mAbs. In the case of tocilizumab without 
hyaluronidase, the SC site lymph flow was 0.0009557 L/h (only 7-fold higher than the original 
value). This proves that the SC injection site lymph flow was altered when hyaluronidase co-
formulation strategy was used. For the SC profiles where this strategy was not used, the SC 
injection site lymph flow was relatively less affected. 
 
2.3.4 Comparison of lymphatic trunk-LN clearance with pI and bioavailability of mAbs 
The estimated lymphatic trunk-LN clearance was compared with the pI (Figure 2.7) and bioavailability 
(Figure 2.8) of mAbs. The interstitial space has overall anionic charge due to cell surface of various 
immune cells in the LNs. The mAbs with higher pI had higher values of the estimated lymphatic trunk-
LN clearance. The lymphatic trunk-LN clearance increased with decrease in bioavailability (obtained 
from literature) of the mAbs (Figure 2.8). This suggests that the model accounted for the lymphatic 
proteolysis of mAbs after SC administration. This may indicate that the lymphatic system was an 





Figure 2.5: Observed and the model fitted SC PK profiles. a) adalimumab, b) anifrolumab, c) belimumab-Healthy, 
d) belimumab-patients, e) canakinumab, and f) daclizumab (Mean observed PK profiles were used for comparison 
with the model estimates. Observed belimumab 
 
 
Figure 2.6: Observed and the model fitted SC PK profiles. g) golimumab, h) guselkumab, i) infliximab, j) 





Figure 2.7: Correlation of the model estimated lymphatic trunk-LN clearance with the isoelectric point a) Linear 
scale, b) Logarithmic scale 
 
 
Figure 2.8: Correlation of the model estimated lymphatic trunk-LN clearance with the bioavailability a) Linear scale, 
b) Logarithmic scale (Trastuzumab: Co-formulated with hyaluronidase. Tocilizumab: Only one sample co-
formulated with hyaluronidase.) 
 
2.3.5 Sensitivity analysis  
The sensitivity analysis showed that the SC injection site interstitial volume (𝑉"#$ ), SC 
lymph flow (𝐿"#), and lymphatic capillary volume (𝑉'#()), and afferent lymph flow (𝐿-66) were 
responsible for changes in Cmax and Tmax of mAbs (Figure 2.9 S1). In the case of lymphatic trunk-
LN interstitial volume (𝑉'*$ ), increases of the volume by 50- and 100-fold lead to alterations of 
mAb PK profiles, while changes by 0.1 to 10-fold of the original value did not alter Cmax or Tmax. 
The alteration of lymphatic trunk-LN clearance (𝐶𝐿'C) and efferent lymph flow (𝐿%66) mainly 
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lead to modification of the Cmax. In addition, changes in the thoracic duct lymph flow (𝐿1234) and 
central lymphatic volume (𝑉'*+#/0) did not impact PK of mAbs. This indicates that transit through 
the initial lymphatic system after SC injection is the rate determining step for mAb absorption 
instead of the thoracic duct. Therefore, SC injection site volume, SC injection site lymph flow, 
lymphatic capillary volume, afferent lymph flow, and efferent lymph flow are important 
physiological parameters for absorption of mAbs. Change in the thoracic duct lymph flow and 
central lymphatic volume did not alter the PK of mAbs (Figure 2.9 S1). Both the Cmax and Tmax 
were sensitive to change in the SC injection site volume, SC injection site lymph flow, lymphatic 
capillary volume, and afferent lymph flow (Figure 2.11 S3 to Figure 2.15 S7). However, changes 
in the efferent lymph flow had no impact on Tmax. In addition, when the lymphatic reflection 
coefficient was increased; Cmax decreased, while Tmax increased. There was no change in the PK 
profile after alteration of the vascular reflection coefficient (Figure 2.10 S2). 
 
2.3.6 Model validation 
Accuracy of the model prediction was evaluated by plotting observed and predicted values 
of Cmax and Tmax (Figure 2.8 S8). In addition, the ratio of observed and predicted Cmax and Tmax 
were plotted with the pI, lymphatic trunk-LN clearance, and bioavailability (Figure 2.17 S9, Figure 
2.18 S10, and Figure 2.19 S11). In the case of Cmax, all predicted values were within 1.2-to 0.5-
fold of the observed literature values. The predicted Tmax was within the range of 1.8 to 0.3-fold of 





In this manuscript, the sequential transfer of mAbs after SC administration via the 
lymphatic system is described using the minimal PBPK model. The SC injection site (interstitial, 
endosomal, vascular), lymphatic capillaries, lymphatic trunk-LNs (interstitial and endosomal), 
central lymphatic system (thoracic duct and cisterna chyli) compartments were used to describe 
the transit of mAbs after SC administration. The rest of the body was modeled with a 2-
compartment model based on the literature IV PK data. The sequential transfer was based on the 
known anatomy of lymphatic system (24-27). However, detailed routes of TP transfer via different 
LNs remain to be investigated further. Also, some individuals may have alterations in the clearance 
patterns, for example the clearance in the arm, shoulder and thigh may be significantly changed 
after radical mastoidectomy. In addition, an injection site may clear into multiple adjacent lymph 
basins. 
The clearance from the interstitial space of the SC injection site was not considered in the 
model, because a previously reported study indicated that protein (hGH) degradation was minimal 
at the SC injection site (5). In addition, simultaneous estimation of the clearance from the SC 
interstitial space and lymphatic trunk-LN interstitial compartment resulted in a minor contribution 
for the SC injection site proteolysis (data not shown). However, the endosomal proteolysis in the 
SC injection site and LNs was considered. The lymphatic trunk-LN interstitial clearance was 
estimated using the minimal PBPK model and the literature SC PK data (Figure 2.4 and Table 
2.4). The estimated clearance differed with dosing and population changes. This alteration of the 
estimated clearance may be due to disease condition, change in formulation, or the differences in 
posttranslational modifications (e.g. glycosylation). These differences were not considered in the 
model. The model demonstrated that the estimated lymphatic trunk-LN clearance of mAbs may 
correlate with the bioavailability (Figure 2.8). The estimated clearance increased when the 
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bioavailability of the mAb decreased. This indicates efficiency of the model to account for the 
proteolysis of mAbs in the lymphatic system. According to the previously published reports, 
proteolysis was not observed after incubation of TPs with the freshly collected lymph, indicating 
absence of any protease enzymes in the lymph (5, 68). In this study, the lymphatic trunk volume 
(which mainly contains lymph fluid) and the LN (which mainly contains lymph node cells) volume 
were combined to represent the compartment responsible for proteolysis of the mAbs. The 
lymphatic trunk-LN compartment was mainly composed of the LN volume. The lymphatic trunk 
volume representing volume of the lymph fluid was very minor (< 7%). 
Sensitivity analysis (Figure 2.9 S1) showed that the lymphatic trunk-LN interstitial space 
proteolysis was important to govern Cmax of the mAbs. The degradation of mAbs in the lymphatic 
system was primarily due to extracellular or interstitial proteolysis. The protease enzymes secreted 
by the LN and other immune cells in the interstitial space may play an important role in reducing 
the bioavailability of mAbs. Intracellular or endosomal proteolysis of mAbs was negligible due to 
FcRn binding-mediated protection. The intracellular proteolysis of mAbs in the lymphatic system 
may be dependent on their uptake by the lymphocytes. In this model, we used endosomal uptake 
rate (R1) from a literature PBPK model (estimated by fitting liver data) (3, 4). Alteration of the 
endosomal uptake rate by 0.1 to 100-fold of the original value did not change the PK of mAbs 
(data not shown). However, in vitro studies to calculate R1 may be useful for an accurate 
understanding of proteolytic processes in the SC injection site and lymphatic system. Disease 
conditions like inflammation may also increase proteolytic activity of the lymph. However, this 
remains to be further investigated. In addition, alteration of the recycling fraction of FcRn bound 
mAb, dissociation constant for antibody FcRn binding, and FcRn concentration did not change PK 
of mAbs (data not shown). 
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Wang et al. (68) confirmed proteolysis of erythropoietin in the presence of rat LN cell 
suspension. The protein completely disappeared after the number of LN cells in the incubation was 
increased. This indicates that LNs are responsible for proteolysis of TPs. In addition, after 
incubation of the protein with the SC tissue homogenate, 90-95% of the parent protein remained 
unaffected (68). Although the authors raised doubts about loss of proteolytic activity during 
preparation of the SC tissue homogenate, this finding corroborates our conclusion that the SC site 
degradation plays a minor role in governing the bioavailability. However, in another study, insulin 
was reported to degrade at the SC injection site (69). Detailed investigation of in vitro proteolysis 
of mAbs in various systems must be done to arrive at more definite conclusion about the cause of 
reduced bioavailability after SC administration.   
The PK studies in humans indicate that variation in the injection site (abdomen and thigh) 
do not have any impact on Cmax and AUC0-∞ of belimumab (44). In another clinical study, 
golimumab’s median Tmax after SC injection in the thigh was 1.25-fold higher than SC injection in 
the abdomen and upper arm. The Cmax after thigh SC injection was 1.33-fold higher than SC 
injection in the upper arm, and the Cmax-abdomen was 1.24-fold higher than that of the upper arm 
(42). This suggests that the volumes of lymphatic compartments and lymph flows may not be 
significantly different for each of the SC injection sites. Therefore, lymphatic volumes and flows 
rates for one injection site may be applied to the other. The calculations used in the model showed 
that the interstitial volume of the lymphatic trunk-LN was similar for various SC injection sites 
(upper arm, abdomen, and thigh) (Table 2.1).  
The prediction accuracy of the model was determined by plotting observed and predicted 
PK parameters (Figure 2.16 S8). There was no correlation of the prediction accuracy of Tmax or 
Cmax with the pI or bioavailability or the estimated lymphatic trunk-LN clearance of mAbs. This 
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confirms that the pI of mAbs did not affect the uptake by lymphatic system. Similarly, lymphatic 
trunk-LN clearance and bioavailability did not govern the prediction accuracy of the model.  
The model also showed that for the mAbs with higher pI, the estimated lymphatic trunk-
LN clearance was greater. The cationic proteins with higher pI have a propensity to bind with the 
anionic cell surfaces and interstitial space (e.g. hyaluronic acid). Higher pI also leads to faster 
clearance of mAbs (70). Similar trend was observed for the mAbs investigated in this study (Figure 
2.7). This correlation may be used to predict the lymphatic trunk-LN clearance based on the known 
pI of mAbs. The lymphatic clearance can be used in the minimal PBPK model to predict SC PK 
of the mAbs. 
Sensitivity analysis of the model parameters indicate that the initial lymphatics are rate 
determining for absorption of mAbs via the SC route. Mainly, the SC injection site lymph flow, 
SC injection site volume, afferent lymph flow, efferent lymph flow, and lymphatic trunk-LN 
volume impacted Tmax, after their alteration by 0.1 to 100-fold of the original value. However, 
thoracic duct lymph flow had no effect on Tmax even after 0.1 to 100-fold changes in its value. 
Therefore, alteration of thoracic lymph duct flows due to disease condition may not alter overall 
PK of mAbs. However, the parameters associated with the initial lymphatic system are important 
to govern the absorption of mAbs and change in those parameters due to the disease conditions 
may significantly alter the SC PK of mAbs.  
It was reported earlier that the PK of mAbs is prone to high inter-subject variability. Factors 
like body weight, age, sex, ethnicity, disease condition, immune status are responsible for 
variations in the PK (71). However, more research is needed to evaluate their influence on 
physiological parameters related to the SC injection site and lymphatic system. The minimal PBPK 
model may be used for prediction of bioavailability of mAbs using in vitro lymphatic proteolysis 
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data and to evaluate the impact of changes in lymphatic flow rates on the PK. In addition, the 
model may be utilized to guide in vitro experiments for mechanistic prediction of the 
bioavailability. This study has explained various physiological parameters related to the SC 
injection site and lymphatic system responsible for regulating the PK of mAbs. 
 
2.5 Conclusion 
The lymphatic trunk-LN clearance was estimated using the minimal PBPK model. The 
physiological parameters related to the SC tissue and lymphatic system were used along with the 
2-compartment IV parameters to construct the minimal PBPK model for prediction of SC PK of 
the mAbs. The model may serve as a platform to utilize the in vitro clearance data from the SC 
tissue and lymphatic system to predict SC PK of mAbs. The LNs were mainly responsible for 
proteolysis of mAbs leading to their reduced bioavailability. Therefore, LN cell suspension may 
be used to generate inputs for the PBPK model. However, the in vitro studies were beyond the 
scope of this manuscript.  Further, this study identified SC injection site lymph flow, afferent 
lymph flow, efferent lymph flow, volumes associated with the SC injection site, and lymphatic 
trunk-LN clearance as important parameters responsible for absorption of mAbs. The lymphatic 
trunk-LN clearance increased with increase in the pI of mAbs. Therefore, the pI of mAbs can be 
used to calculate the lymphatic clearance. Overall, the model is useful to understand disposition of 







2.6 Supplementary Data  
The raw digitalized data of the Figures in this chapter and the SimBiology (Matlab 2017a) 
model file are archived and available free of charge at the University of Kansas ScholarWorks 
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𝐶"#&  Concentration of mAb in the vascular space of SC injection site 
𝐶"#$  Concentration of mAb in the interstitial space of SC injection site 
𝐶"#%  Concentration of mAb in the endosomal space of SC injection site 
𝐶'#() Concentration of mAb in the lymphatic capillary compartment 
𝐶'C$  Concentration of mAb in the interstitial space of lymphatic trunk-LNs 
𝐶'C%  Concentration of mAb in the endosomal space of lymphatic trunk-LNs 
𝐶'*+#/0 Concentration of mAb in the central lymphatic system 
𝐶#/0 Concentration of mAb in the central compartment 
𝐶O/4 Concentration of mAb in the peripheral compartment 
𝑉"#$  SC injection site interstitial volume 
𝑉"#&  SC injection site vascular volume 
𝑉"#%  SC injection site endosomal volume 
𝑉'#() Volume of the lymphatic capillaries 
𝑉'C$  Combined interstitial volume of lymphatic trunk-LNs after SC injection in thigh 
𝑉'C%  
Combined endosomal volume of all LNs to which the mAb is exposed after SC 
injection in thigh 
𝑉'*+#/0 Volume of central lymphatic system 
𝑉#/0 Volume of the central compartment 
𝑉O/4 Volume of the peripheral compartment 
𝐿"#  Lymph flow at the SC injection site 
56 
 
𝐿-66 Lymph flow afferent to LNs 
𝐿%66 Lymph flow efferent to LNs 
𝐿1234 Thoracic duct lymph flow 
𝑄"#  Blood flow at the SC injection site 
s' Lymphatic reflection coefficient 
s& Vascular reflection coefficient 
𝐶𝐿'C Clearance of mAb in the lymphatic trunk-LN interstitial compartment 
𝐶𝐿%093+"#  Endosomal clearance of mAb in the SC injection site 
𝐶𝐿%093+'C Endosomal clearance of mAb in LNs 
𝐶𝐿#/0 Clearance of mAb from the central compartment 
𝐾MN Transfer rate constant from the central compartment to the peripheral compartment 
𝐾NM Transfer rate constant from the peripheral compartment to the central compartment 
𝑓I"#  Unbound fraction of mAb in SC tissue 
𝑓I'C Unbound fraction of mAb in lymphatic trunk and LNs 
𝐶%093 Concentration of endogenous mAb in endosomal compartment 
𝑅1 Endosomal uptake rate of antibody 
𝑅2 Endosomal return rate of antibody 
𝐹𝑅 Recycling fraction of FcRn bound mAb 
𝐾𝑑 Dissociation constant for antibody FcRn binding 



















Figure 2.9 S1: Effect of change in various model parameters on pharmacokinetics of mAbs.  
(PK profiles 1-11 in each diagram represent 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50-, and 100-fold of the 
original parameter value as mentioned in the Table 1. The pharmacokinetic profile ‘5’ (circles) represents the 
original parameter value. In the case of lymphatic clearance, estimated lymphatic clearance of golimumab was 





Figure 2.10 S2: Effect of change in lymphatic reflection coefficient and vascular reflection coefficient on PK of 
mAbs.  
(The lymphatic reflection coefficient was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 1.5-, 2-, 2.5-, 3-, 3.5-, 4-, 4.5-, 5- 
folds of the original parameter value as mentioned in Table 2. The vascular reflection coefficient was altered by 
0.01-, 0.1-, 0.105-, 0.21-, 0.31-, 0.42-, 0.52-, 0.63-, 0.73-, 0.84-, 0.94-, 1-, 1.05-folds of the original parameter 




Figure 2.11 S3: Cmax and Tmax values with alteration of SC injection site volume. 
The volume was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50-, and 100-fold of the original parameter 
value as mentioned in Table 1.  







Figure 2.12 S4: Cmax and Tmax values with alteration of SC injection site lymph flow. 
The lymph flow was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50-, and 100-fold of the original parameter 
value as mentioned in Table 1. (Dashed line indicates the original value of the SC injection site lymph flow used 
in the model) 
 
 
Figure 2.13 S5: Cmax and Tmax values with alteration of lymphatic capillary volume  
The volume was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50-, and 100-fold of the original parameter 









Figure 2.14 S6: Cmax and Tmax values with alteration of afferent lymph flow  
The lymph flow was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50-, and 100-fold of the original parameter 




Figure 2.15 S7: Cmax and Tmax values with alteration of efferent lymph flow  
The lymph flow was altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50-, and 100-fold of the original parameter 







Figure 2.16 S8: Accuracy of Cmax and Tmax prediction by the minimal PBPK model 
 
 
Figure 2.17 S9: Accuracy of the predicted Cmax and Tmax in comparison with the isoelectric point of mAbs 
 
 
Figure 2.18 S10: Accuracy of the predicted Cmax and Tmax in comparison with the estimated lymphatic trunk-LN 






Figure 2.19 S11: Accuracy of the predicted Cmax and Tmax in comparison with the bioavailability of mAbs 
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Chapter 3 : Effect of iron oxide nanoparticles on the secondary structure and oxidation of 
rat growth hormone 
3.1 Introduction 
The higher order structure (secondary, tertiary, quaternary) of TPs is important for their 
biological activity and stability. Chemical changes including oxidation of susceptible amino acids 
can lead to alteration in the secondary structure of TPs, resulting in increased aggregation, altered 
pharmacokinetics, lower biological activity and increased immunogenicity (1). For example, 
bioavailability may be reduced leading to a need to increase the dose or alteration in the therapy 
due to generation of antibodies against the TP (1, 2).   
The trace metal impurities arising from buffers, formulation components, and processing 
equipment, can oxidize TPs by catalyzing formation of reactive oxygen species (ROS). Soluble 
iron impurities can generate superoxide radicals, hydrogen peroxide (H2O2), and hydroxyl radicals 
leading to oxidation of TPs (3, 4). In addition, iron oxide nanoparticles (IONPs) may be present 
due to iron containing equipment used during the manufacturing process or produced by injection 
needles during TP administration. A protein corona can develop around nanoparticles (NPs) 
leading to formation of larger particle sizes and possibly aggregation (5). Protein-NP interactions 
may induce changes in protein secondary structure (6) and further oxidation of TPs (7). It is not 
known, however, if altered secondary structure of TPs due to binding to IONPs can influence the 
extent of TP oxidation. We therefore selected rat growth hormone (rGH) as a model protein for 
studying oxidation, since it is a very similar analogue to the TP human growth hormone, and is 






The IONPs (g-form) were purchased from US Research Nanomaterials Inc (Houston, TX). 
The 2,2′-azobis (2-methylpropionamidine) dihydrochloride (AAPH), H2O2, potassium 
ferricyanide, 1,10-phenanthroline monohydrate, sodium citrate tribasic dihydrate, and ascorbic 
acid were purchased from Sigma Aldrich (St. Louise, MO). Ammonium bicarbonate, 
dithiothreitol, iodoacetamide, LC/MS-grade water (0.1% v/v formic acid), acetonitrile (0.1% v/v 
formic acid), monobasic sodium dihydrogen phosphate, sulfuric acid, hydrogen fluoride, dibasic 
sodium hydrogen phosphate, and the Pierce BCA protein assay kit (Product number: 23227) were 
purchased from Fisher Scientific (Waltham, MA). Trypsin/Lys-C (mass spectrometry grade) was 
purchased from Promega (Madison, WI). Amicon ultra-0.5 centrifugal filter devices (10, 30, 100 
kDa cut off membranes) were purchased from Millipore Inc., (Bedford, MA, USA). The 4-
aminomethyl-benzylsulfonic acid (ABS) was synthesized according to a published method (9, 10).  
 
3.2.2 Production of rat growth hormone (rGH) 
rGH is a 22-kDa protein of 191 amino acids and contains two disulfide bonds (11, 12). The 
cDNA plasmid for the rGH protein sequence (Protein accession number- AAI66872) was 
synthesized by GenScript (New Jersey, USA) and inserted into pET-28a(+) using the NdeI and 
BamHI restriction sites (13). The pre-protein sequence (first 25 amino acids) was removed from 
the original cDNA; the resulting rGH amino acid sequence is shown in the Figure 3.9 S1. The 
plasmid was transformed into DH5a competent E. coli cells, and a single colony was expanded, 




The confirmed rGH plasmid was transformed into BL21 (DE3) E. coli, and rGH was 
produced by shake flask culture using a protocol modified from previously reported methods (12, 
14, 15). In brief, the E. coli cells were cultured in lysogeny broth (LB) media with kanamycin (40 
µg/mL) and chloramphenicol (40 µg/mL) at 37 °C and 200 rpm shaking. Once an optical density 
(at 600 nm) of around 0.6 was reached, cultures were induced with isopropyl β-d-1-
thiogalactopyranoside (IPTG) (1.0 mM). After 4 h, cultures were centrifuged at 1391´g for 10 min 
and the cell pellet was suspended in lysis buffer (50 mM Tris-hydrochloride, 500 mM sodium 
chloride, pH 8). The mixture was then sonicated (50% power, 4 cycles ´ 30 sec, at 4 °C) until it 
was no longer viscous using a Fisher Scientific Sonic Dismembrator Model 500 (Waltham, MA). 
Inclusion bodies of rGH were isolated by centrifuging at 6,000´g (at 4 °C) for 30 min, followed 
by a water wash, and then dissolved in 6 M urea lysis buffer. The proteins were refolded by 
following proprietary procedures (KanPro Research Inc.), and then dialyzed in phosphate buffer 
saline (PBS), containing 88 mM mannitol. rGH was analyzed for purity using SDS-PAGE (Figure 
3.10). Intact mass analysis of the protein confirmed the molecular weight of 21.9 kDa and also 
showed around 15% initial oxidation (+16 m/z) on two methionine residues (M1 and/or M5). This 
modification probably occurred during purification and refolding (data not shown). Detailed 
analysis of a tryptic digest of the protein (sequence coverage of ~92%) using mass spectrometry 
was previously reported (14).  
 
3.2.3 Chemical Oxidation of rGH and sample processing 
Chemically accelerated oxidation of rGH was induced with H2O2 or AAPH, in the absence 
or presence of IONPs. The final concentrations of rGH, H2O2, AAPH and IONPs were 0.8 mg/mL, 
2 mM, 10 mM and 1.7 mM, respectively. This mixture was incubated at 37 °C for 3 or 24 h while 
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shaking at 100 revolutions/minute. For H2O2-induced oxidation, 10 µL of catalase solution (1 
mg/mL) were added to quench the oxidation. AAPH was removed using Amicon ultra-0.5 
centrifugal filters (10 kDa). The oxidized rGH was processed further for reduction of disulfide 
bonds using dithiothreitol and alkylation of cysteine residues using iodoacetamide to prevent 
reformation of disulfide bonds. The disulfide bonds are reduced to increase efficiency of tryptic 
digestion by disrupting secondary structure of the protein. The disulfide bonds of rGH were 
reduced by adding 100 µL of dithiothreitol (26 mM stock solution in 50 mM ammonium 
bicarbonate buffer) and incubating this mixture at 45 °C for 1 h. The reduced cysteine residues 
were alkylated by adding 200 µL of IAA (50 mM stock solution in 50 mM ammonium bicarbonate 
buffer) and incubating at 37 °C for 1 h. 
 
3.2.4 Trypsin/Lys-C digestion of rGH 
The reduced and alkylated rGH (0.4 mg) was precipitated with 700 µL of 0.5 M perchloric 
acid. The samples were centrifuged at 15000´g for 15 min and the resulting pellet was suspended 
in 400 µL of 50 mM ammonium bicarbonate buffer (pH 7.5). Four µg of trypsin/Lys-C were added 
and the samples were incubated at 37 °C overnight. The proteolytic digests were centrifuged using 
10 kDa centrifuge filters to remove trace amounts of undigested rGH and trypsin/Lyc-C. The 
tryptic peptides were stored at -20 °C until mass spectrometry analysis. 
 
3.2.5 Mass spectrometry  
A nanoAcquity UPLC (Waters Corporation, Milford, MA) connected to a Xevo Q-TOF 
(Waters Corporation, UK) was used for for LC-ESI-MS experiments. Tryptic peptides were first 
trapped on an UPLC Symmetry C18 nanoAcquity trap column (5 µm, 180 µm ´ 20 mm, Water 
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Corporation) and then separated on an UPLC Peptide CSH C18 nanoAcquity column (1.7 µm, 75 
µm ´ 250 mm, Waters Corporation). For separation, we applied an optimized method and 
parameters that we previously reported (9). In silico tryptic digestions of rGH and prediction of 
fragment ions were performed with web based applications, Proteomics Toolkit (Institute of 
Systems Biology, Seattle, WA) and ProteinProspector 5.21.2 (The University of California, San 
Francisco, CA). 
 
3.2.6 Fluorogenic derivatization  
Tyrosine residues of rGH were oxidized with AAPH in the absence or presence of IONPs. 
The oxidation products were derivatized with ABS to produce a fluorescent benzoxazole according 
to our previously described protocol (9, 16). Briefly, rGH oxidized by AAPH was buffer 
exchanged with 100 mM sodium phosphate buffer (pH 9) using 10-kDa cutoff filter devices. 
Potassium ferricyanide and rGH and were mixed in a molar ratio of 30:1. ABS (10 mM) was 
added, and the mixture incubated at ambient temperature in the dark for 90 min. Fluorescence (360 
nm-excitation/ 490 nm-emission) was measured using a SpectraMax GeminiXS microplate 
fluorometer (Molecular Devices, Sunnyvale, CA).    
 
3.2.7 Fourier transform infrared (FTIR) 
Spectra of rGH solutions (1 mg/mL) with varying concentrations of IONP (0.42 to 1.47 
mM) were acquired with a Bruker Tensor 27 FTIR spectrometer fitted with a Bio-ATR cell 
(Bruker, Billerika, MA). Scans were recorded from 600 to 4000 cm-1 at a resolution of 1 cm-1. The 
FTIR spectra were acquired after 10 and 30 min as well as 1 and 2 h incubation period at ambient 
temperature. In addition, rGH and rGH-IONP mixtures were incubated at increasing temperatures 
from 15 to 85 °C at increments of 2.5 °C/step with a 120 s equilibration time, and 128 scans/step. 
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The phosphate buffer-IONP-mixture was used for background subtraction of the FTIR spectra. 
Opus 6.5 (Bruker, Billerika, MA) was used for baseline and atmospheric correction, generation of 
second derivative spectra and smoothing.  
 
3.2.8 Circular Dichroism (CD) spectroscopy 
Far-ultraviolet (UV) CD spectra were acquired using a Chirascan spectropolarimeter 
(Applied Photophysics, Surrey, United Kingdom). The final concentration of rGH was 13 µM and 
the path-length for CD measurements was 0.2 cm. The spectra were acquired from 200 nm to 260 
nm with increasing temperature from 10 to 90 °C at increments of 2.5 °C. The secondary structures 
were estimated from the CD spectra using the BeStSel web tool (17).       
 
3.2.9 Measurement of iron content in IONPs 
The iron content of the IONP was determined with a 1,10-phenanthroline colorimetric 
assay (18-20). The 10% IONP-water dispersion was diluted 5-fold and centrifuged at 500´g for 
30 min. The pellet of IONPs was discarded and the supernatant was used for further analysis. 
Dynamic light scattering (Zetasizer Helix, Malvern Instruments Ltd., Malvern, UK) was used to 
measure particle size of the supernatant IONPs (~20 nm, 99.2% by number analysis, standard 
deviation of 3.8 nm) suspended in phosphate buffer (pH 7.4). The supernatant IONPs (1 mL) were 
treated with 0.5 ml of 8 N sulfuric acid (H2SO4), 0.4 ml of 15% w/v ascorbic acid solution, and 
0.2 mL of 48% hydrogen fluoride (HF) at 70 °C for 1 h. Ascorbic acid was used as a reducing 
agent to convert Fe+3 to Fe+2 ions, so only Fe+2 ions would be available to form a colored complex 
after addition of 1,10-phenanthroline (0.5 ml, 100 mM). After incubating at 40 °C for 25 min, the 
reaction was quenched with 1 mL of 5% w/v boric acid, and then incubated at ambient temperature 
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for a further 30 min. Samples were then diluted 20-fold with sodium citrate tribasic dihydrate 
buffer (10% w/v). Absorbance measurements at 510 nm were acquired with a SpectraMax Plus 
Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA), using a calibration curve of 
known Fe+2 concentrations.  Fe+2 content was assayed in the same manner without the ascorbic 
acid reduction step. No color developed in any samples (data not shown), indicating that the IONPs 
did not have a significant Fe+2 content and were composed predominantly of Fe+3.       
  
3.2.10 Statistical analysis 
ChemoSpec (R package) was used in RStudio (Version 1.1.383) (Boston, MA) to perform 
principle component analysis (PCA) on FTIR (21). Analysis of variance (ANOVA) and Tukey’s 
multiple comparison test were used to compare the degree of oxidation measured using the mass 
spectrometry and ABS derivatization technique. ANOVA and Tukey’s test were performed using 
GraphPad Prism 6 (La Jolla, CA). 
 
3.3 Results 
3.3.1 Identification of oxidized residues 
 




In this study, H2O2 and AAPH were used to induce the chemical oxidation of rGH. Tryptic 
digestions were used to monitor the oxidation of methionine residues (Table 3.1). The MS/MS 
spectrum (Figure 3.1) of tryptic peptide TDMELLR shows that the M73 represents an oxidation 
target. The fragment ions y5, y6 and b3 indicate an increase in mass of 16 Da. In addition, a 
characteristic loss (22) of methanesulfenic acid (CH3SOH, 64 Da) from the y5 ion was observed. 
This further confirmed the oxidation of methionine (M73) to methionine sulfoxide in the tryptic 
peptide TDM(+16)ELLR. Other methionine-containing peptides, DLEEGIQALMQELEDGSPR, 
IFTNSLMFGTSDR and MFPAMPLSSLFANAVLR, also showed oxidation of the methionine 
amino acids. The MS/MS spectra for these tryptic peptides are described in the Figure 3.11 S3, 
Figure 3.12 S4, Figure 3.13 S5, Figure 3.14 S6, Figure 3.15 S7 and Figure 3.16 S8, and the results 
are summarized in Table 3.1.  
Table 3.1: Oxidized residues and the associated tryptic peptides 
Oxidized residue  Tryptic peptide 






The y11 and y13 ions indicated that M124 was oxidized on the tryptic peptide 
DLEEGIQALM(+16)QELEDGSPR (Figure 3.11 S3). In the case of tryptic peptide 
IFTNSLMFGTSDR; y7, y8, y9, y10 and y11 ion fragments were increased by 16 Da (Figure 3.12 
S4). Therefore, M102 was oxidized to methionine sulfoxide in the tryptic peptide 
IFTNSLM(+16)FGTSDR.  
Similarly, 2 peaks of oxidized tryptic peptide MFPAMPLSSLFANAVLR were observed 
in the chromatogram (data not shown) with the same m/z. CID of the first peak (Figure 3.13 S5) 
showed that either M1 or F2 were oxidized, because the fragment ions b2, b3, b4, b5 and b6 
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showed an increase in mass by 16 Da. The fragment ion which could distinguish oxidation 
specifically on M1 or F2 was not found. While in the case of the second peak of tryptic peptide 
MFPAM(+16)PLSSLFANAVLR, which eluted earlier, we concluded that the M5 amino acid was 
oxidized because the y13 and b5 fragment ions increased in mass by 16 Da (Figure 3.14 S6).  
The tryptic peptide MFPAMPLSSLFANAVLR was oxidized at both the M1/F2 and M5 
amino acids. This can be shown by the increase in mass by 32 Da for the b5 fragment ion (Figure 
3.15 S7). The other fragment ions (y13, y15, b4) were increased in mass by 16 Da, indicating 
oxidation of M1/MF2 and M5.  
In the case of tryptic peptide FDANMR, oxidation of M149 was confirmed using the 
MS/MS fragmentation pattern (Figure 3.16 S8). Oxidation of M149 can be shown by the increase 
in mass of the y4 and y5 fragment ions by +16 Da. Furthermore, a characteristic loss of 
methanesulfenic acid (CH3SOH, 64 Da) from the y4 and y5 ions was observed. These fragments 
confirmed that FDANM(+16)R was oxidized at the M149 residue. However, this oxidized tryptic 
peptide co-eluted with the native non-oxidized FDANMR. Hence the fragmentation pattern had 
several fragment ions which originated from the native peptide, and they were not assigned.  
   
3.3.2 Quantification of oxidized residues in the presence of IONPs  
Out of the 7 methionine (M) residues (Table 3.1) found in rGH, 6 residues (M1, M5, M73, 
M102, M124, and M149) were monitored for oxidation in the presence of IONPs and H2O2. The 
peptide containing M179 was not found in the mass spectrometric analysis. According to the in 
silico tryptic digestion, M179 is part of a small 4 amino acid peptide. We hypothesize that this 




The oxidation of M73 was significantly reduced (P≤0.01) after 24 h of incubation in the presence 
of H2O2 and IONPs compared to H2O2 alone (Figure 3.2). After 3-h incubation of rGH with IONPs 
and H2O2, however, M73 showed more oxidation (P≤0.001) than to H2O2 alone. In addition, M73 
oxidation was significantly reduced (P≤0.001) in the presence of IONPs compared to the samples 
with H2O2 alone. The MFPAMPLSSLFANAVLR peptide was also di-oxidized (M1/F2 and M5) 
by H2O2 (Figure 3.17 S9). Similarly, IONPs suppressed oxidation of M102 and M124. In contrast, 
no difference in oxidation in the presence and absence of IONPs was observed for the peptide 
M149. The results indicate that the IONPs suppressed H2O2-induced oxidation of the tryptic 
peptides. 
After incubation with AAPH, M1, M5, and M149 were either not oxidized or much less 
oxidized compared to incubation with H2O2. However, in the case of M73, M102 and M124, 
similar results were observed as shown previously with H2O2-induced oxidation (Figure 3.18 S10). 
Overall, IONPs reduced AAPH-induced oxidation of rGH. 
 
3.3.3 AAPH-induced rGH oxidation in the presence of IONPs and use of fluorogenic 
derivatization for analysis 
The tyrosine residues (7 total) in rGH were oxidized by AAPH in the presence and absence 
of IONPs. The degree of oxidation was monitored using a fluorogenic derivatization method 
(Figure 3.3). Tyrosine oxidation was reduced in the presence of IONPs. Control groups such as 
buffer-IONPs, buffer, buffer-IONPs-AAPH were also studied (Figure 3.19 S11). These controls 
confirmed that IONPs did not have any negative or positive impact on the fluorescence signal used 




Figure 3.2: Methionine (M73, M102, M124, M149) oxidation in the presence of IONPs and H2O2 using mass 
spectrometry 
The results are presented as percent of the peptide oxidized (mean and standard deviation, n=2). Percent oxidation 
of various rGH residues was calculated based on the mass spectrometry derived area under the curve of oxidized 
and non-oxidized peptides. 
3 h and 24 h groups were compared separately using 2-way ANOVA. The symbols above each column indicate the 3 
or 24 h time points of rGH+IONP+H2O2. 
NS: Not significant, ****: P≤0.0001, ***: P≤0.001, **: P≤0.01, * P≤0.05 
 
In another experiment, rGH was incubated with AAPH after removing the IONPs to 
monitor if the effect of IONPs on rGH is reversible. This study showed that even after removing 
the IONPs, tyrosine residues were not oxidized. Briefly, the IONPs were removed by filtration at 
the end of 3 h-incubation. Following that, the same amount of additional AAPH was added and 
incubated again for 3 h. A control sample was kept without any additional AAPH. Differences 
between these 2 samples were not statistically significant as shown by ANOVA and Tukey’s 




The reduced oxidation (Figure 3.3) of rGH in presence of IONPs may be due to loss of 
protein during the sample processing steps or due to binding to the IONPs. This possibility of the 
loss of rGH was eliminated by another experiment in which a rGH-IONP mixture and rGH alone 
were filtered and the filtrate was measured for protein concentration using a BCA assay. There 
was no significant loss of the protein during filtration with and without IONPs (Figure 3.21 S13). 
This suggests that the reduced oxidation of rGH seen in the presence of IONPs is due to the IONP 
binding and not due to loss of protein in the sample processing steps. 
 
Figure 3.3: Oxidation of tyrosine amino acids of rGH in presence of AAPH (10 mM) and IONPs (1.7 mM) after 3-h 
of incubation at 37 °C 
Samples were compared using 1-way ANOVA. The symbols above each column indicate comparison with 
rGH+IONP+AAPH. NS: Not significant, ****: P≤0.0001, ***: P≤0.001, **: P≤0.01, * P≤0.05 
 
3.3.4 Use of FTIR to monitor IONP-induced changes in rGH secondary structure  
The FTIR spectra of rGH were altered after incubation with various concentrations of 
IONPs, suggesting change in the secondary structure of the protein. Incubation with 1.7-mM 
IONPs appears to lead to aggregation or intramolecular beta sheet formation resulting in the 
creation of new bands denoted as a and b, corresponding to 1627 and 1640 cm-1 signals, 
respectively (Figure 3.22 S14). Lower concentrations of IONPs (0.85 and 0.42 mM) leads to more 
subtle structural changes in the a-helical region (1653 cm-1) (Figure 3.4 and Figure 3.22 S14) (23). 
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In the presence of 0.85 and 0.42 mM IONPs (1-and 2-h samples) the a-helical band is split into 2 
bands at 1649 and 1657 cm-1. This again indicates that the interaction of rGH with the IONPs can 
lead to structural changes. In addition, there is an increase in intensity of the band around 1680 
cm-1 compared to pure rGH and the 0-h sample of the rGH-IONP mixture. The spectra of IONPs 
and phosphate buffer showed that they did not affect the FTIR bands of rGH (Figure 3.23 S15).  
The rGH-IONP mixture and rGH were subjected to increasing temperatures from 15 to 85 
°C and FTIR spectra were acquired (Figure 3.5). Both groups (with and without IONPs) showed 
alteration of FTIR spectra with increasing temperature indicating aggregation as manifested by 
increase in the 1620 cm-1 peak. In the presence of IONPs, an additional band at around 1650 cm-1 
(marked with a dashed red line) was detected in the ‘y region’ (Figure 3.5). The intramolecular 
beta sheets are generally observed at 1635 and 1689 cm-1 (24). In this study, bands at 1620 and 
1694 cm-1 were observed, which may indicate intramolecular beta sheet formation. Therefore, the 
transition temperature for rGH in presence of IONPs is monitored using the 2nd derivative 
absorbance at 1620 and 1694 cm-1 with increasing temperature from 15 to 85 °C (Figure 3.24 S16). 
The transition temperature in the presence and absence of IONPs was similar (around 55 °C). 
 
Figure 3.4: Second derivative FTIR spectra of rGH and rGH-IONP mixtures (0.85 mM IONPs) at 25 °C A) 
Unzoomed and B) Zoomed (1640-1700 cm-1) 
FTIR spectra were acquired as duplicates or triplicates. Mean representative spectra are shown. Blue: rGH alone; 





Figure 3.5: FTIR spectra of A) rGH and B) rGH+IONP (1.7 mM) from 15 to 85 °C 
(x and y indicate altered regions due to IONPs, dashed red line shows an additional feature observed at 1650 cm-1 
due to IONPs) 
 
3.3.5 Principal component analysis (PCA) on the FTIR spectra 
Principal component analysis was used to differentiate the FTIR spectra generated using 
rGH and various combinations of the rGH-IONP mixture (Figure 3.6). The spectra of mixtures of 
rGH and IONPs based on various IONP concentrations (1.7, 0.85 and 0.42 mM) and incubation 
times (0, 10, 30 min, 1 and 2 h) were separated effectively using PCA. Principle component (PC)1 
and PC2 were the major components with contribution of around 50 and 35%, respectively (Figure 
3.6-A). Longer incubation (2.5 h) of rGH with 1.7-mM IONPs leads to aggregation and hence it 
was not included in the PCA. However, other time points (0, 10 and 30 min) of 1.7-mM IONP and 
rGH mixture were included. Pure rGH, 0-h (1.7, 0.85, 0.42 mM IONP and rGH) and 10-min (1.7 
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mM IONP and rGH) time points were in the same region of PC1 vs PC2 plot which constitutes the 
first cluster. There is a second cluster for the 1- and 2-h time points of rGH and 0.42 or 0.85 mM 
IONP mixtures. In addition, the 30-min time point of rGH and 1.7-mM IONP mixture present in 
the third cluster. In the case of PC3 vs. PC1 scores plot, pure rGH sample was separated from the 
other samples (Figure 3.6-B). However, the PC3 contribution was minor (10%) compared to PC1 
and PC2 (Figure 3.25 S17). Loading plots (Figure 3.26 S18) indicate that PC1 and PC2 had 
significant contributions to the a-helical FTIR spectral region (1645 to 1660 cm-1) (23). 
 
Figure 3.6: Principal component analysis of FTIR spectra for rGH and rGH-IONP mixture at various concentrations 
of IONPs and incubation times A) Plot of PC1 and PC2, B) Plot of PC1 and PC3 
Principal component analysis on the FTIR data acquired with increasing temperature from 
15 to 85 °C showed two separate clusters for the rGH and rGH-IONP mixture (Figure 3.7). PC1 
was the major component with contribution of around 82%, while PC2 had a lower contribution 
of around 18% (Figure 3.27 S19). Loading plots indicate that PC1 and PC2 had contributions from 
the FTIR bands indicating aggregation (1627 cm-1), intramolecular beta sheets (1640 cm-1) and a-




Figure 3.7: Principal component analysis of FTIR spectra acquired for rGH and the rGH-IONP mixture at different 
temperatures (15 to 85 °C ramping with a 2.5 °C interval) 
3.3.6 Circular Dichroism (CD) spectroscopy 
CD spectroscopy was also used to evaluate any change in rGH secondary structure due to 
IONPs. For this study, 3 IONP concentrations were tested (1.7, 0.85 and 0.42 mM). Higher 
concentration of IONPs (1.7 and 0.85 mM) interfered with the CD spectra (data not shown). 
Interference from 0.42 mM IONPs was minimal; therefore, this concentration was selected for 
further analysis. The spectra of rGH alone and the rGH-IONP mixture were identical for lower 
temperatures (Figure 3.29 S21); however, at higher temperatures (57.5, 60 and 62.5 °C) the CD 
spectra were different with the negative a-helical band at 208 nm clearly reduced in intensity 
(Figure 3.8). The transition temperature (66 °C) calculated by measurements at 220 nm was similar 
for rGH samples with and without IONPs (Figure 3.30 S22). The percent a-helical structure 
decreased with increases in temperature for both rGH and the rGH-IONP mixture. The 
contribution of a-helical structure at 40 °C was around 27% and 10% for rGH and the rGH-IONP 
mixture, respectively. For other temperature points, the a-helical contribution was similar for both 
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the rGH and rGH-IONP mixture, although visual checks on the CD spectra at different 
temperatures showed minor changes (Figure 3.8). 
 
Figure 3.8: Comparison of CD spectra of rGH and rGH-0.42 mM IONP mixtures at various temperatures A) 10 °C, 
B) 30 °C, C) 40 °C, D) 57.5 °C, E) 60 °C, F) 62.5 °C 
 
3.4 Discussion 
Soluble metal impurities from manufacturing processes can oxidize sensitive amino acids 
via metal-catalyzed reactions that may significantly impact the stability and shelf life of TP 
formulations. Along with the soluble iron impurities, IONPs may be present as contaminants 
during TP manufacturing due to the iron shredding of manufacturing equipment. IONPs may also 
be shredded by the injection needle used during administration of TPs. Therefore, it is important 
to investigate the impact of IONPs on the oxidation of proteins. Whereas multiple studies have 
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confirmed the iron induced oxidation of TPs, our results show that the extent of H2O2- and AAPH-
mediated oxidation of rGH is reduced in the presence of IONPs. This result is in marked contrast 
with the well-known effect of soluble iron impurities leading to increased oxidation of TPs (3). In 
our specific case, this may be due to formation of a rGH protein corona around the IONPs, leading 
to protection from oxidation by the external oxidizing agents. These results were confirmed by 
monitoring H2O2 levels using the FOX assay in the presence of IONPs and without any protein. 
The H2O2 levels did not decrease significantly during 24 h of incubation in the presence of the 
IONPs (data not shown). This indicated that oxidant levels were not decreased by the IONPs and 
that suppression of rGH oxidation was due to interaction with the IONPs. In contrast, Jayaram et 
al reported that titanium dioxide nanoparticles generated ROS (hydroxyl radicals and superoxide 
radicals), which catalyzed oxidation of corona proteins around the nanoparticles (25). 
The oxidation of methionine residues (M73, M102, and M124) was suppressed due to 
IONPs. However, M149 oxidation was not altered even in the presence of IONPs (Figure 3.4). 
This could be due to the location of methionine residues in the 3-D structure of rGH. M124 is a 
part of a-helix number 3 in rGH (11), while other methionine residues are a part of the non-helical 
polypeptide chains. In the case of M124, the 24-h sample containing IONPs significantly differed 
(P≤0.0001) in a level of oxidation from the one without IONPs. The H2O2-mediated oxidation of 
other methionine residues was either not significantly different (M149) in the presence of IONPs 
or affected to a lesser extent (M73, M102) relatively. These results indicate that the location of 
methionine residues in the 3-D structure of TP may alter the impact of IONPs on the extent of their 
oxidation. 
The metal oxide nanoparticles can also alter the secondary structure of TPs and enzymes. 
For example, zinc oxide nanoparticles increased the amount of a-helical structure of lysozyme as 
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demonstrated by CD and FTIR (26). In addition, airborne nanoparticles changed the expression of 
proteins by human bronchial epithelial cells (27). Furthermore, alteration of human growth 
hormone structure due to metal ions (cobalt and iron) was reported previously (28, 29). Trace 
amounts of copper (>75 ppb) were responsible for cabonylation and aggregation of TPs (30). 
Formation of higher order clusters of the proteins and gold nanoparticles was demonstrated (5). In 
another study, CD data showed alteration of secondary structure of cytochrome c due to interaction 
with gold nanoparticles (31). In this study, the rGH-IONP interaction was studied using FTIR and 
CD. 
Incubation with 1.7-mM IONPs probably leads to aggregation or formation of 
intramolecular beta sheets as shown by the new FTIR bands at 1627 and 1640 cm-1 (Figure 3.22 
S14). Similar FTIR bands were reported previously as indicating protein aggregation (1620 cm-1) 
and intramolecular beta sheets (1635 cm-1) (24, 32). Various amounts of IONPs were tested to 
analyze alteration of rGH FTIR spectra. PCA was successfully used to distinguish the FTIR spectra 
of various combinations of rGH-IONP mixtures and incubation time points. Thus, PCA may be 
useful to distinguish various formulations and provide stability evaluation of TP formulations. The 
CD spectra of rGH and the rGH-IONP mixture were different at higher temperatures (Figure 3.8). 
These findings probably reflect a role for IONPs in the alteration of the secondary structure of 
rGH. In the case of proteins having predominantly a-helical structure, 2 bands are usually observed 
at around 220 and 208 nm (17). Similar bands were observed for rGH and rGH-IONPs mixtures. 
In addition, the CD spectra of rGH were similar to the previously published CD spectra acquired 
from human growth hormone, human pituitary growth hormone and ovine pituitary lactogenic 
growth hormone (33, 34). In addition, tryptophan fluorescence intensity was used to study effect 
of IONPs on the tertiary structure of the protein (Figure 3.31 S23) (35). There was not, however, 
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any significant difference in the CD-determined transition temperatures at various IONP 
concentrations. 
It is well known that oxidation of TPs may lead to alteration of their secondary structure. 
The changes in secondary structure of TPs can result in alteration of their biological activity, 
pharmacokinetics and immunogenicity (1). However, it is not clearly known if modification of the 
secondary structure of TPs due to the metal-nanoparticle interactions (i.e. a corona) can influence 
the degree of oxidation. These changes in oxidation and secondary structure may impact the overall 
stability of the TPs. Although this study showed decreased oxidation of rGH and altered secondary 
structure due to IONPs, the oxidation and secondary structure evaluation experiments were 
conducted separately using different time points and temperature conditions. For example, the 
FTIR data were recorded over 2 h and rGH oxidation was studied until 24 h. Furthermore, FTIR 
and CD spectra were recorded with increasing temperatures up to 90 °C, while oxidation 
experiments were conducted at a much lower constant temperature (37 °C). Therefore, these 
experiments do not directly establish a correlation between altered secondary structure and the 
degree of rGH oxidation. Overall, this study has demonstrated decreased oxidation and alteration 
in the secondary structure of rGH in the presence of IONPs. It should be emphasized that, effect 
of the change in secondary structure on the extent of oxidation is not yet clear and must be 
investigated further.  
 
3.5 Conclusion 
This study found that IONPs can affect the degree of oxidation and secondary structure of 
rGH. In contrast to other reports of increased oxidation of proteins catalyzed by metal 
nanoparticles, the IONPs decreased H2O2- and AAPH-mediated oxidation. This could indicate that 
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the protein corona that may form around the IONPs could be protective against some forms of 
chemically induced oxidation. Furthermore, the relative rates of oxidation for amino acids in 
different locations changed, which means that IONPs may alter the composition of peptide 
epitopes derived from degraded TPs. Proteins are also oxidized in the presence of soluble iron. 
However, the rGH protein incubated with IONPs, was not oxidized when compared to control 
incubations without IONPs. Thus, IONPs generated from the manufacturing processes may impact 
the stability of TPs, as shown by the altered degree of oxidation and secondary structure. In 
addition, the utility of PCA was demonstrated on the categorization of different protein stress 
conditions. 
 
3.6 Supplementary Data 
 













Figure 3.11 S3: Collision induced dissociation (CID) of oxidized peptide DLEEGIQALM(+16)QELEDGSPR 















































Figure 3.17 S9: Methionine/phenylalanine 
(M1/F2, M5) oxidation in the presence of IONPs 
and H2O2 using mass spectrometry 
 
Figure 3.18 S10: Methionine (M73, M102, 
M124) oxidation in the presence of IONPs and 






Figure 3.19 S11: AAPH-induced (tyrosine) oxidation of rGH using fluorogenic derivatization assay and 
comparison with the control groups 
 
 








Figure 3.21 S13: Loss of protein content due to filtration in the presence of IONPs 
 
 







Figure 3.23 S15: FTIR buffer controls to demonstrate that mannitol in the rGH formulation and IONPs incubated 
with the protein did not interfere with the spectra 
 
 





Figure 3.25 S17: Contribution of principle components (PC) to explain variance in the FTIR data acquired for 




Figure 3.26 S18: Loadings for PC1 and PC2 for the FTIR data acquired for rGH and rGH-IONP incubation at 






Figure 3.27 S19: Contribution of principle components (PC) to explain variance in the FTIR data acquired for 
rGH and rGH-IONP mixture at various temperatures (15 to 85 °C) 
 
 
Figure 3.28 S20: Loadings for PC 1 and PC 2 for the FTIR data acquired for rGH and rGH-IONP mixture at 






Figure 3.29 S21: Circular dichroism (CD) spectra for rGH and rGH-IONP mixture with increasing temperature 






Figure 3.30 S22: A) CD measurement at 220 nm with increasing temperature B) First derivative of 220 nm 




Figure 3.31 S23: Effect of IONPs on tryptophan fluorescence intensity with increasing temperature from 15 to 90 
°C 
The instrument used for measuring tryptophan fluorescence was manufactured by Fluorescence Innovations Inc. 
(Minneapolis, MN). Previsouly reported methods were used (35). 
 
3.7 References 
1. Torosantucci R, Schöneich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: 
structural and biological consequences. Pharm Res. 2014;31(3):541-553 
2. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. 
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid 
arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis & 
Rheumatology. 2006;54(12):3782-3789 
3. Mozziconacci O, Ji JA, Wang YJ, Schöneich C. Metal-catalyzed oxidation of protein 
methionine residues in human parathyroid hormone (1-34): Formation of homocysteine 
and a novel methionine-dependent hydrolysis reaction. Mol Pharm. 2013;10(2):739-755 
4. Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: 
mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 
1995;48(5):490-500 
5. Moerz ST, Kraegeloh A, Chanana M, Kraus T. Formation mechanism for stable hybrid 
clusters of proteins and nanoparticles. ACS nano. 2015;9(7):6696-6705 
6. Treuel L, Malissek M. Interactions of nanoparticles with proteins: Determination of 
equilibrium constants. Cellular and Subcellular Nanotechnology: Methods and Protocols. 
2013:225-235 
7. Sakulkhu U, Mahmoudi M, Maurizi L, Salaklang J, Hofmann H. Protein corona 
composition of superparamagnetic iron oxide nanoparticles with various physico-
chemical properties and coatings. Sci Rep. 2014;4:5020 
8. Fradkin AH, Mozziconacci O, Schöneich C, Carpenter JF, Randolph TW. UV 
photodegradation of murine growth hormone: chemical analysis and immunogenicity 
consequences. Eur J Pharm Biopharm. 2014;87(2):395-402 
101 
 
9. Bommana R, Mozziconacci O, Wang YJ, Schöneich C. An Efficient and Rapid Method 
to Monitor the Oxidative Degradation of Protein Pharmaceuticals: Probing Tyrosine 
Oxidation with Fluorogenic Derivatization. Pharm Res. 2017;34(7):1428-1443 
10. Sharov VS, Dremina ES, Galeva NA, Gerstenecker GS, Li X, Dobrowsky RT, Stobaugh 
JF, Schöneich C. Fluorogenic tagging of peptide and protein 3-nitrotyrosine with 4-
(aminomethyl) benzenesulfonic acid for quantitative analysis of protein tyrosine nitration. 
Chromatographia. 2010;71(1-2):37-53 
11. Abdel-Meguid SS, Shieh H-S, Smith WW, Dayringer HE, Violand BN, Bentle LA. 
Three-dimensional structure of a genetically engineered variant of porcine growth 
hormone. Proceedings of the National Academy of Sciences. 1987;84(18):6434-6437 
12. Fradkin AH, Boand CS, Eisenberg SP, Rosendahl MS, Randolph TW. Recombinant 
murine growth hormone from E. coli inclusion bodies: Expression, high-pressure 
solubilization and refolding, and characterization of activity and structure. Biotechnol 
Prog. 2010;26(3):743-749 
13. NCBI. Growth hormone 1 (Rattus norvegicus) GenBank: AAI66872.1. 2018 June 8, 
2018. Available from: https://www.ncbi.nlm.nih.gov/protein/187469098/. 
14. Mozziconacci O, Stobaugh JT, Bommana R, Woods J, Franklin E, Jorgenson JW, Forrest 
ML, Schöneich C, Stobaugh JF. Profiling the Photochemical-Induced Degradation of Rat 
Growth Hormone with Extreme Ultra-pressure Chromatography–Mass Spectrometry 
Utilizing Meter-Long Microcapillary Columns Packed with Sub-2-µm Particles. 
Chromatographia. 2017;80(9):1299-1318 
15. Nelson CA, Lee CA, Fremont DH. Oxidative refolding from inclusion bodies. In. 
Structural Genomics and Drug Discovery: Springer; 2014. p. 145-157. 
16. Torosantucci R, Mozziconacci O, Sharov V, Schöneich C, Jiskoot W. Chemical 
modifications in aggregates of recombinant human insulin induced by metal-catalyzed 
oxidation: covalent cross-linking via michael addition to tyrosine oxidation products. 
Pharm Res. 2012;29(8):2276-2293 
17. Micsonai A, Wien F, Kernya L, Lee Y-H, Goto Y, Réfrégiers M, Kardos J. Accurate 
secondary structure prediction and fold recognition for circular dichroism spectroscopy. 
Proceedings of the National Academy of Sciences. 2015;112(24):E3095-E3103 
18. Perry R, San Clemente C. Determination of iron with bathophenanthroline following an 
improved procedure for reduction of iron (III) ions. Analyst. 1977;102(1211):114-119 
19. Anastácio AS, Harris B, Yoo H-I, Fabris JD, Stucki JW. Limitations of the ferrozine 
method for quantitative assay of mineral systems for ferrous and total iron. Geochim 
Cosmochim Acta. 2008;72(20):5001-5008 
20. Fortune W, Mellon M. Determination of iron with o-phenanthroline: a 
spectrophotometric study. Industrial & Engineering Chemistry Analytical Edition. 
1938;10(2):60-64 
21. Hanson BA. ChemoSpec: Exploratory Chemometrics for Spectroscopy. R package 
version 4.4.97. Available from: https://cran.r-project.org/package=ChemoSpec. 
22. Guan Z, Yates NA, Bakhtiar R. Detection and characterization of methionine oxidation in 
peptides by collision-induced dissociation and electron capture dissociation. J Am Soc 
Mass Spectrom. 2003;14(6):605-613 




24. Dong A, Prestrelski SJ, Allison SD, Carpenter JF. Infrared spectroscopic studies of 
lyophilization-and temperature-induced protein aggregation. J Pharm Sci. 
1995;84(4):415-424 
25. Jayaram DT, Runa S, Kemp ML, Payne CK. Nanoparticle-induced oxidation of corona 
proteins initiates an oxidative stress response in cells. Nanoscale. 2017;9(22):7595-7601 
26. Elbrecht D, Mitchell J, Lekey A, Marquardt K, Knight K, Smith J, DeLong R. 
Nanoproteomics: The convergence of protein science and nanotechnology with important 
applications for bio-element metal and etal oxide nanoparticles. Reviews in Nanoscience 
and Nanotechnology. 2013;2(5):365-381 
27. Park SK, Jeon YM, Son BS, Youn HS, Lee MY. Proteomic analysis of the differentially 
expressed proteins by airborne nanoparticles. J Appl Toxicol. 2011;31(5):463-470 
28. Saboury A, Ghourchaei H, Sanati M, Atri M, Rezaei-Tawirani M, Hakimelahi G. Binding 
properties and structural changes of human growth hormone upon interaction with cobalt 
ion. J Therm Anal Calorim. 2007;89(3):921-927 
29. Atri M, Saboury A, Rezaei-Tavirani M, Sanati M, Moosavi-Movahedi AA, Sadeghi M, 
Mansuri-Torshizi H, Khodabandeh M. Binding properties and conformational change of 
human growth hormone upon interaction with Fe3+. Thermochim Acta. 2005;438(1-
2):178-183 
30. Kryndushkin D, Rao VA. Comparative effects of metal-catalyzed oxidizing systems on 
carbonylation and integrity of therapeutic proteins. Pharm Res. 2016;33(2):526-539 
31. Aubin-Tam M-E, Hamad-Schifferli K. Gold nanoparticle− cytochrome C complexes: the 
effect of nanoparticle ligand charge on protein structure. Langmuir. 2005;21(26):12080-
12084 
32. Dong A, Matsuura J, Manning MC, Carpenter JF. Intermolecular β-sheet results from 
trifluoroethanol-induced nonnative α-helical structure in β-sheet predominant proteins: 
Infrared and circular dichroism spectroscopic study. Arch Biochem Biophys. 
1998;355(2):275-281 
33. Bewley TA, Li CH. Circular dichroism studies on human pituitary growth hormone and 
ovine pituitary lactogenic hormone. Biochemistry. 1972;11(5):884-888 
34. Lim JY, Kim NA, Lim DG, Kim KH, Jeong SH. Effects of thermal and mechanical stress 
on the physical stability of human growth hormone and epidermal growth factor. Arch 
Pharm Res. 2015;38(8):1488-1498 
35. Wei Y, Larson NR, Angalakurthi SK, Russell Middaugh C. Improved Fluorescence 
Methods for High-Throughput Protein Formulation Screening. SLAS Technol. 2018:1-13 
103 
 
Chapter 4 : A minimal physiologically based pharmacokinetic model describing the altered 
metabolism of midazolam due to inflammation   
4.1 Introduction 
Inflammation and other disease conditions are known to alter the expression of cytochrome 
P450 enzymes (CYPs) due to increased proinflammatory cytokine levels (1, 2). Typically, 
cytokines such as IL-6, IL-1β, IFN-γ and TNF-α are increased during inflammation. Elevated 
cytokine levels can lead to suppression of various CYPs. Increased IL-6 levels downregulate 
CYP3A4, while TNF-α downregulates CYP2C19 (3-5). Thus, inflammation and elevated cytokine 
levels may cause disease-drug interactions by altering the pharmacokinetics (PK) and specifically 
clearance of drugs that are metabolized by CYPs. 
Cytokine-mediated CYP suppression is believed to occur through a nuclear receptor, 
hepatic nuclear factor-4α (HNF-4α). Elevated IL-6, TNF-α and IL-1β can inhibit the action of 
HNF-4α. HNF-4α is involved in the regulation of pregnane X receptor (PXR) and constitutive 
androstane receptor (CAR) that are responsible for regulating the expression of CYP3A4 following 
exposure to some xenobiotics (4). Elevated IL-6 is known to down-regulate CYP3A4, CYP2C9, 
CYP2C19 and CYP1A2, while TNF-α down-regulates CYP2C19 (3, 6). In this study, the 
hypothesis was that the elevated cytokines during inflammation (diseased state) would suppress 
the expression of mouse cyp3a11 (76% amino acid homology with the human CYP3A4) (7), which 
may lead to changes in PK of its substrates. 
In the case of glucose-6-phosphate isomerase (GPI)-mediated inflammation in DBA/1 
mice, circulating levels of IL-6 and TNF-α were increased (8). This GPI model of inflammation is 
frequently used to test the anti-inflammatory activity of new chemical entities (NCEs) (9). The PK 
of NCEs is generally studied using healthy mice, and the data are often used to inform dose 
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selection for demonstration of efficacy in an inflammation model. Therefore, it is worthwhile to 
develop a mechanistic approach, which includes the CYP activity differences in healthy versus 
diseased mice, to inform dose selection for the pharmacological assays utilizing the GPI model. 
The overall goal of this study was to build a model for dose selection, which can more accurately 
predict dose response in the diseased state based off healthy animal-PK data and in vitro 
metabolism data (healthy and diseased). 
Midazolam (MDZ), a known CYP3A4 substrate, was selected as a model compound for in 
vitro metabolism and PK studies. Lipopolysaccharide- (10, 11) and carrageenan-induced 
inflammation (12) both have been reported to alter the PK of MDZ. Metabolism of MDZ was 
evaluated using liver microsomes prepared from healthy and GPI-treated mice. According to the 
published in vitro experiments in humans and rodents, MDZ is mainly metabolized by CYP3A to 
form 1-OH-MDZ and 4-OH-MDZ. The phase 1 metabolites of MDZ may be further conjugated 
with glucuronide to form 1-OH-MDZ-glucuronide and 4-OH-MDZ-glucuronide. In a PK study 
using chimeric mice with humanized livers (PXB mice), 1-OH-MDZ, 4-OH-MDZ, 1,4-diOH-
MDZ, and 1-OH-MDZ-glucuronide were detected in plasma. However, 4-OH-MDZ and 1-OH-
MDZ-glucuronide were not detected in severe combined immune deficient (SCID) mice (10, 13-
15). 
In this work, a minimal physiologically based pharmacokinetic (PBPK) model was 
constructed to predict PK of MDZ in mice with GPI-mediated inflammation. The model equations 
and methodology could be applied to other drugs to predict altered PK parameters in disease 






The methods section is divided into various subsections describing the in vitro metabolism, 
PK, Liquid Chromatography-Mass Spectrometry (LC-MS) analysis, minimal PBPK model, and 
quantitation of cytokines and mRNA. Briefly, the rate of 1-OH-MDZ formation in the liver 
microsomes was used to assess the degree of inflammation-mediated suppression of MDZ 
metabolism. In addition, MDZ PK parameters were compared in the healthy and GPI-treated mice. 
Finally, both the in vitro (in healthy and GPI mice) and PK data (in healthy mice) were used to 
build the minimal PBPK model. The in vitro microsomal data defined metabolism of MDZ from 
the liver and intestines, while the parameters associated with a 2-compartment model were 
estimated using the healthy animal PK data. These estimated PK parameters were used to define 
the central and peripheral compartments of the minimal PBPK model (Figure 4.4). The 2-
compartment model PK parameters from GPI mice were used to illustrate that the PK in the 
diseased state can be predicted using in vitro (healthy and diseased animals) and healthy animal 
PK data. In addition, serum cytokine levels were measured in the healthy mice and on days 12 and 
21 after GPI treatment. The mRNA-levels of cyp3a11, cyp2c29 and cyp2d26 in liver were also 
measured on days 1, 5, 8 and 15 after GPI treatment. 
 
4.2.1 Animals 
Male DBA/1 mice (Harlan Laboratories, Indianapolis, IN) were acclimatized for 3 days 
and housed as 4 animals per cage or individually if a cage mate was not available. Animals were 
approximately 9-10 weeks old at the start of the study. A 12-h light and 12-h dark cycle was 
maintained throughout the study. Mice were fed and given access to water ad libitum. All 
procedures were in compliance with the Guide for the Care and Use of Laboratory Animals: Eighth 
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Edition, (Institute for Laboratory Animal Research, The National Academies Press, Washington, 
D.C.); and the National Institutes of Health, Office of Laboratory Animal Welfare (NIH 
publication no. 85-23, revised 1985). Whenever possible, procedures were designed to avoid or 
minimize discomfort, distress, and pain to the animals. 
 
4.2.2 GPI treatment 
The mice were treated with GPI according to a previously published protocol with a few 
modifications (16). Briefly, a 4-mg/mL solution of recombinant human GPI was mixed with an 
equal volume of complete Freund’s adjuvant. This final 2 mg/mL solution of GPI was used for the 
treatment. A 100-µL (200-µg) injection of the above solution was administered at both sides of the 
tail base to induce inflammation. 
 
4.2.3 Preparation of mouse liver microsomes (MLM) and in vitro experiments 
Healthy and diseased mice were sacrificed using cardiac puncture either immediately or on 
day 12 after the GPI treatment, and the livers were collected and stored at -80° C until immediately 
before use. The MLM were prepared using previously reported protocols (17, 18). The protein 
content of MLM was measured using the bicinchoninic acid assay using a reported procedure (19). 
Liver microsome kinetic studies of 1-OH-MDZ and 4-OH-MDZ formation were carried out by 
following the reported methods (13, 15, 20). Based on the linear relationship of MDZ metabolism 
and MLM protein concentration from 0.1 to 0.5 mg/mL (data not shown), a protein content of 0.1 
mg/mL was selected for all subsequent microsomal experiments. A 2-min incubation time was 
selected for kinetic experiments based on an earlier study, which reported that the incubation time 
for formation of the metabolites was linear up to 20 min using MLM and human liver microsomes 
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(HLM) (20). The rate of 1-OH-MDZ and 4-OH-MDZ formation was measured at concentrations 
of MDZ ranging from 0 to 250 µM. The data obtained was fitted to a substrate inhibition kinetics 
using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA). 
 
4.2.4 Pharmacokinetics of MDZ 
MDZ was administered via intravenous (IV) or oral (PO) routes at 1 mg/kg or 5 mg/kg, 
respectively. The PO bioavailability of MDZ was low (F=0.023) according to the previously 
published report (21). Therefore, a higher PO dose was selected. Approximately 20 µL of blood 
was collected using a capillary and applied directly on dried blood spot (DBS) cards at time points 
as follows: IV- 0.08, 0.166, 0.33, 0.5, 1, 2, 4, 6, 8 h and PO- 0.166, 0.33, 0.5, 1, 2, 4, 6, 8 h. The 
DBS samples were analyzed for MDZ, 1-OH-MDZ, 4-OH-MDZ and 1-OH-MDZ-glucuronide. 
The MDZ used for dosing in the PK studies was obtained from Hospira (Lake Forrest, IL). The 
MDZ, 1-OH-MDZ and 4-OH-MDZ standards were obtained from Cerilliant Corporation (Round 
Rock, TX), while the 1-OH-MDZ-glucuonide standard was obtained from Toronto Research 
Chemicals (Ontario, Canada).    
Pharmacokinetics of MDZ in the healthy and diseased mice were compared using 3 animal 
groups as shown in the Figure 4.1. The first group was not treated with GPI and was kept for 21 
days before MDZ dosing and DBS sample collection. The second group was treated with GPI on 
day 10 of the study, while the third group was treated with GPI on day 1. Finally, MDZ was 
administered on day 21, and DBS samples were subsequently collected to measure blood 
concentration of the analytes (MDZ, 1-OH-MDZ, 4-OH-MDZ and 1-OH-MDZ-glucuronide). The 
healthy and diseased animal PK parameters were obtained using non-compartmental analysis 
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(NCA) using SimBiology (Matlab R2017a). Analysis of variance (ANOVA) and Tukey’s 
comparison test were used to determine differences in PK parameters in healthy and diseased mice.  
 
 
Figure 4.1: Protocol for the pharmacokinetic study 
 
4.2.5 Measurement of fraction unbound in plasma and liver microsomes 
The fraction unbound MDZ to the proteins in the plasma and liver microsomes was 
determined at 37° C using a HT dialysis micro equilibrium device with a 12-14kDa molecular 
weight cutoff (Gales Ferry, CT) in a stirred 37˚C bath. The microsomal protein concentration was 
0.5 mg/mL in phosphate buffer (100 mM, pH 7.4), and the plasma was thawed on the day of use 
and adjusted to pH 7.4 using phosphoric acid. The samples were collected from both the protein 
side and buffer side of the membrane after 0 and 4.5 h. The signal for MDZ was monitored by LC-
MS/MS with a calibration curve range from 1 to 5000 nM and an acceptable interference peak less 
than 25% of the lower limit of quantitation. Deviations of less than ±30% were acceptable for the 
calibration curve samples. Fraction unbound was calculated as a ratio of MDZ concentration in the 
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buffer and protein chambers. Percent recovery (data not shown) was calculated by dividing the 
sum of the buffer and protein chambers by the time 0 concentration. 
 
4.2.6 Liquid Chromatography-Mass Spectrometry (LC-MS) analysis of DBS samples  
Analysis of MDZ and its metabolites was performed using a previously published protocol 
with modifications as described (22). Stock solutions of each analyte were combined and serially 
diluted to produce a range of working solutions, which were used to fortify control mouse blood 
to yield calibration standards (1 to 10,000 ng/mL). These calibration standards were then spotted 
onto DBS cards and allowed to dry at room temperature. A 3-mm punch of each study and standard 
DBS sample was removed and placed in separate wells of 96-well plates, then extracted with a 
methanol/acetonitrile (1:1, v/v) solution containing internal standards.  The resulting extracts were 
analyzed using an ABSciex API4000 triple quadrupole mass spectrometer LC-MS/MS instrument 
(Applied Biosystems/MDS; Foster City, CA) run in positive ion mode using a ThermoFisher 
Betasil C18 2x20-mm 5-micron HPLC column (ThermoFisher Scientific, Waltham, MA) with 
0.1% formic acid/water and an acetonitrile gradient to achieve the chromatographic separation.  
Each compound was detected and quantified with analyte specific selected reaction monitoring 
(SRM) (M+H)+ transitions (MDZ: m/z 326.1>291.2, 1-OH-MDZ: m/z 342.1>203.2, 4-OH-MDZ: 
m/z 342.1>234.2, 1-OH-MDZ-glucuronide: m/z 518.2>324.1, D4-MDZ: m/z 330.1>295.2, and D4-
1-OH-MDZ: m/z 346.1>328.1).  The mass spectrometer quadrupoles were tuned to achieve unit 
resolution (0.7 Da at 50% FWHM) and data were acquired and processed with Analyst 1.4.2 
(Applied Biosystems/MDS). The limit of detection was set at 5-fold greater than the noise. The 




4.2.7 LC-MS analysis of the in vitro samples  
The in vitro metabolism samples were analyzed by LC-MS/MS using an ABSciex QTrap 
6500 triple quadrupole mass spectrometer (Applied Biosystems/MDS; Foster City, CA) equipped 
with a TurboIonSpray interface and operated in a positive ion mode.  The analytes were separated 
using an Ace Ultracore SuperC18 column (2.1x30-mm, 5-micron) with a gradient elution of 5-
mM ammonium bicarbonate and acetonitrile. Each compound was detected and quantified by 
analyte specific SRM (M+H)+ transitions (1-OH-MDZ: m/z 342.1>203.0, 4-OH-MDZ: m/z 
342.1>234.0, and D4-1-OH-MDZ: m/z 346.1>203.0). The mass spectrometer quadrupoles were 
tuned to achieve unit resolution (0.7 Da at 50% FWHM) and data were acquired and processed 
with Analyst 1.6 (Applied Biosystems/MDS). 
4.2.8 Construction of the Minimal PBPK model 
The minimal PBPK model with a 2-compartment PK model was constructed using 
SimBiology (Matlab R2017a) (Figure 4.4). The mouse physiological parameters obtained from 
literature (23-26), experimental values and the 2-compartment model estimated parameters (Table 
4.4, Table 4.5, and Table 4.6) were used to construct the minimal PBPK model. The volumes of 
the central and peripheral compartments and rate constants for transfer of MDZ between the central 
and peripheral compartments were estimated by fitting the healthy-animal IV PK data with the 2-
compartment PK model. ‘Nonlinear mixed-effects problems’ was used as the estimation method 
for the 2-compartment model fitting. The in vitro kinetic data for 1-OH-MDZ and 4-OH-MDZ 
formation were used in the minimal PBPK model to define the rate of hepatic metabolism, while 
the literature data were used for the gut metabolism (Table 4.5) (27). In the case of hepatic 
metabolism, Vmax-1-OH-MDZ-Liver, Vmax-4-OH-MDZ-Liver, Km-1-OH-MDZ-Liver and Km-4-OH-MDZ-Liver values in 
both the healthy and the diseased animals were obtained experimentally and a Vmax-1-OH-MDZ-Liver-
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Healthy/Vmax-1-OH-MDZ-Liver-GPI ratio (0.55) was calculated (Table 4.5). Experimental in vitro data were 
not available for gut metabolism, therefore literature values were used (27). It was assumed that 
the Vmax-1-OH-MDZ-gw-Healthy/Vmax-1-OH-MDZ-gw-GPI ratio for intestine was same as that for the hepatic 
metabolism. The values of gut Vmax-1-OH-MDZ-gw and Vmax-4-OH-MDZ-gw for day 12 GPI mice were 
calculated using the ratio 0.55. Scaling of Vmax-1/4-OH-MDZ-Liver and Vmax-1/4-OH-MDZ-gw was done for 
the entire liver and intestine, respectively so that the values could be used in the minimal PBPK 
model. A scaling factor of 45 milligrams of liver microsomal protein per gram of mouse liver was 
used as mentioned in the previous report (28). For the intestinal Vmax-1/4-OH-MDZ-gw scaling, 23.6 
milligrams of intestinal microsomal protein per gram of intestine was used (29). CYP3A is almost 
exclusively responsible for metabolism of MDZ to form hydroxylated metabolites (20, 27). 
However, additional nonCYP3A metabolism in the gut was estimated by fitting the PO healthy 
animal PK data to the minimal PBPK model. This additional metabolism was defined by Vmax-
nonCYP3A-MDZ-gw and Km-nonCYP3A-MDZ-gw (Table 4.5). Similar to previously mentioned gut Vmax-1-OH-
MDZ-gw calculations, the ratio of 0.55 was used to calculate Vmax-nonCYP3A-MDZ-gw for GPI treated mice, 
while Km-nonCYP3A-MDZ-gw was assumed as constant for the healthy and disease condition. Sensitivity 
analysis was performed on the model input parameters as shown in Figure 4.2 and Figure 4.3. The 
model parameters were altered by -100 to +500% of the original values listed in Table 4.4 and 




Figure 4.2: Sensitivity analysis for Cmax after MDZ PO administration. 
Effect of altered parameters (a) Vmax-1-OH-MDZ-Liver  b) Km-1-OH-MDZ-Liver) from approximately -100 to +500% of the healthy 
animal original value as mentioned in Table 5. 
 
 
Figure 4.3: Sensitivity annalysis on Cmax after PO MDZ administration. 
Effect of altered parameters from approximately -100 to +100% of the healthy original value as mentioned in Table 





Figure 4.4: Schematic representation of the minimal PBPK model 
 
The minimal PBPK model was adopted from a previously published study by Zhang et al 
(30). The model can be described by equations 1 to 6 (4.6 Supplementary Information), which 
were solved by the solver type ‘Ordinary differential equations (ODE) 15s’ (stiff/NDF). Equation 
1 represents absorption of MDZ through the gut lumen. Equation 2 and 5 defines MDZ metabolism 
in the intestine and liver, respectively. Equation 3 is the ‘Well-Stirred’ gut model (31), which was 
used in equation 2 for calculation of fraction unbound in gut (fu,g). Equation 4 defines the transit 
of MDZ from the intestine and central compartment to the portal vein and then to the liver. The 
transfer of MDZ from the liver to central compartment and further exchange with the peripheral 
compartment is shown in equation 6. Cgw, Cpv, Cliv, Ccen, Cper are concentration (nmol/L) of MDZ 
in gut wall, portal vein, liver, central compartment and peripheral compartment, respectively. Agl 
is the amount (nmol) of MDZ in the gut lumen compartment. All other parameters in the equations 
1 to 6 are mentioned in Table 4.4 and Table 4.5. Assumptions in the minimal PBPK model are 
described as follows. a) The in vitro literature data used to define intestinal metabolism of MDZ 
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was applicable to the minimal PBPK model (27). b) Suppression of intestinal CYP450 activity due 
to the GPI-mediated inflammation was same as in the liver. c) The mouse physiological parameters 
(blood flows, organ volumes) were same for the healthy and GPI treated diseased mice. 
 
4.2.9 Quantitation of serum cytokines  
Serum cytokines were quantitated using a mouse proinflammatory multiplex kit (Meso 
Scale Diagnostics, Rockville, MD) (32). Briefly, serum samples were diluted 2-fold with diluent, 
and 50 µL of diluted sample was added to each well on a pro-inflammatory panel plate (96-well) 
and incubated for 2 h at room temperature.  After washing 3 times with the wash buffer, 25 µL of 
detection antibody solution was added per well, followed by an additional 2-h incubation at room 
temperature.  The wells were washed 3 times with the wash buffer, and 150 µL of 2X Read Buffer 
T was added to each well. The plate was immediately read on a MSD Sector S 600 (Meso Scale 
Diagnostics, Rockville, MD). Sample concentrations were calculated using calibration curves that 
were fitted using a 4-parameter logistic model with a 1/Y2 weighting. ANOVA was used to 
establish statistical differences in cytokine levels for the healthy and diseased mice.  
 
4.2.10 RNA isolation and cyp mRNA level detection by quantitative polymerase chain reaction 
(qPCR) 
For each animal, 50-150 mg of frozen liver tissue was homogenized in the presence of 800 
µL of Trizol™ (Thermo Fisher Scientific, Waltham, MA) using FastPrep® lysing matrix D beads 
and the FastPrep®-24 homogenizer (MP Biomedicals, Santa Ana, CA). The homogenate was 
chilled on ice and was clarified by centrifugation (10,000 x g for 4 minutes). The clarified 
homogenate was mixed with an equal volume of 100% ethanol, and then processed using the 
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Direc-Zol™ RNA isolation spin column protocol, including DNAse1 treatment (Zymo Research, 
Irvin, CA). The concentration and yields of the purified total liver RNA were determined using a 
Nanodrop™ 8000 spectrophotometer. Then 100 ng of purified RNA was used in a reverse 
transcription reaction to generate cDNA using TaqMan® High Capacity RNA-to-cDNA Kit 
(Applied Biosystems, Foster City, CA). The cDNA reaction was diluted 5-fold with sterile water 
and used for TaqMan® based quantitative PCR analysis for cyp3a11, cyp2c29, and cyp2d26 
mRNA targets as well as for the PPIB house-keeping gene mRNA normalizer control. The qPCR 
data were collected on a 7900HT Real Time PCR instrument (Applied Biosystems). The data were 
analyzed using ExpressionSuite® software (Thermo Fisher Scientific, Waltham, MA), and cyp 
target mRNA levels were expressed relative to the PPIB mRNA normalizer control. The unpaired 
T-test was used to establish statistical differences between day-1 and -12 cyp mRNA levels. 
 
4.2.11 Statistical analysis 
Chi square test was used to find association between predicted and observed PK profiles 
using Excel Chi square test function (33). ANOVA, T-test, Tukey’s multiple comparison test were 
performed using GraphPad Prism 6 (La Jolla, CA). Box-plots for cytokines and cyp-mRNA were 
plotted using RStudio (Version 1.1.383). 
 
4.3 Results 
4.3.1 Effect of GPI-mediated inflammation on the in vitro metabolism of MDZ 
The rate of 1-OH-MDZ formation was higher in the MLM prepared from heathy mice as 
compared to the MLM prepared from GPI-treated mice (Figure 4.5 and Table 4.1). The Vmax-1-OH-
MDZ-Liver was suppressed by 44% in the diseased mice-MLM as compared to the healthy. The Vmax-
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1-OH-MDZ-Liver was 2.047 (± 0.005) nmol/min/mg in MLM of the healthy mice and 1.143 (± 0.021) 
nmol/min/mg in MLM of the GPI treated mice (P value ≤0.0001). This indicated that the GPI-
mediated inflammation suppressed cyp3a11 expression, leading to lower Vmax-1-OH-MDZ-Liver. 
However, Km-1-OH-MDZ-Liver was relatively unchanged (P value=0.151) in the MLM prepared from the 
healthy versus diseased mice. In the case of 4-OH-MDZ, both Vmax-4-OH-MDZ-Liver and Km-4-OH-MDZ-Liver 
were suppressed with the MLM prepared from the diseased animals as compared to healthy 
animals (P value ≤0.0001) (Figure 4.5 and Table 4.2). The higher Km-4-OH-MDZ-Liver as compared to 
Km-1-OH-MDZ-Liver suggested that 4-OH-MDZ formation is a minor route of metabolism as compared 
to 1-OH-MDZ (P value ≤0.0001). Similar results concluding lower contribution of 4-OH-MDZ as 
compared to 1-OH-MDZ were reported earlier (13, 15). 
 
Figure 4.5: Rate of metabolite formation with increasing MDZ concentration in MLM prepared from the healthy and 
GPI-treated mice a) 1-OH-MDZ and b) 4-OH-MDZ 
MLM were prepared using livers collected from the healthy mice and on day 12 after GPI treatment. Lines indicate 
fitted metabolite formation kinetics. Experimental values are represented as filled circles or squares with standard 
deviation (n=3). 
 
Table 4.1: Rate of 1-OH-MDZ formation in MLM prepared using livers from the healthy and GPI treated mice 
(Fitted to substrate inhibition kinetics) 
Parameter Healthy mice Mice treated with GPI (Day 12) 
Vmax-1-OH-MDZ-Liver 
(nmol/min/mg) 
2.047 (± 0.005) 1.143 (± 0.021)* 
Km-1-OH-MDZ-Liver (nM) 5630 (±160) 6130 (± 380)# 
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Ki-1-OH-MDZ-Liver (nM) 478400 (± 16000) 228760 (± 13000) 
Each value represents the mean ± standard deviation (n=3)  
Vmax-1OH-MDZ-Liver: Maximum rate of metabolic conversion of MDZ to 1-OH-MDZ in liver 
Km-1-OH-MDZ-Liver: MDZ concentration corresponding to half of Vmax-1OH-MDZ-Liver 
Ki-1-OH-MDZ-Liver: Substrate inhibition constant 
*Day 12-Vmax-1-OH-MDZ-Liver was significantly different than the healthy-Vmax-1OH-MDZ-Liver  
(Unpaired T-test with P≤0.0001) 




Figure 4.6: Comparison of a) AUC0-8h and b) 
clearance of MDZ in healthy and GPI-treated mice 
after MDZ IV administration (1 mg/kg). 
Pharmacokinetic parameters were obtained using 
NCA and represented as mean and standard 
deviation. ANOVA and Tukey’s test were used for 
comparison of Day 12 and Day 21 after GPI 
treatment with healthy mice. (NS: Not significant, *: 
P≤0.05, **: P≤0.01)  
 
Figure 4.7: Comparison of a) AUC0-8h and b) 
Clearance/F of MDZ in healthy and GPI-treated 
mice after MDZ PO administration (5 mg/kg).  
Pharmacokinetic parameters were obtained using 
NCA and represented as mean and standard 
deviation. ANOVA and Tukey’s test were used for 
comparison of Day 12 and Day 21 after GPI 
treatment with healthy mice. (NS: Not significant, *: 
P≤0.05, **: P≤0.01) 
 
4.3.2 Pharmacokinetics of MDZ in healthy and GPI-treated mice 
In the case of IV dosing, plasma MDZ profiles were available through 2 h for healthy and 
day 21 GPI mice, while for day 12 mice, plasma MDZ levels were available through 4 h (Figure 
4.11). In the case of PO dosing, for day 12 and 21, PK were available through 8 h, while for PO 




Figure 4.8: Pharmacokinetic profile of 1-OH-MDZ after IV and PO MDZ administration 
 
 
Figure 4.9: Pharmacokinetic profile of 4-OH-MDZ after IV and PO MDZ administration 
individual variability in the PK parameters (Table 4.3, Figure 4.6 and Figure 4.7) was high. This 
inter-individual variability may be due to variability in the IL-6 levels (2700 to 6900 pg/mL) 
(Figure 4.15) on day 12 leading to differences in the CYP suppression and PK of MDZ. Figure 4.8  
and Figure 4.9 describe PK profiles of 1-OH-MDZ and 4-OH-MDZ, respectively after IV and PO 
MDZ administration. The AUC0-8h of 1-OH-MDZ after IV and PO administration of MDZ is 
shown in Figure 4.10. Fraction unbound in plasma (fu,p) for both the healthy and diseased states 
was measured and was same for both of these samples (Table 4.4). 
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Table 4.2: Rate of 4-OH-MDZ formation in MLM prepared using livers from the healthy and GPI treated mice 
(Fitted to substrate inhibition kinetics) 
Parameter Healthy mice Mice treated with GPI (Day 12) 
Vmax-4-OH-MDZ-Liver 
(nmol/min/mg) 
2.201 (± 0.06) 0.772 (± 0.01)* 
Km-4-OH-MDZ-Liver (nM) 83200 (± 2000) 42490 (± 1000)# 
Ki-4-OH-MDZ-Liver (nM) 622500 (± 125000) 3279000 (± 492000) 
Each value represents the mean ± standard deviation (n=3) 
Vmax-4OH-MDZ-Liver: Maximum rate of metabolic conversion of MDZ to 4-OH-MDZ in liver 
Km-4-OH-MDZ-Liver: MDZ concentration corresponding to half of Vmax-4OH-MDZ-lv 
Ki-4-OH-MDZ-Liver: Substrate inhibition constant 
* Day 12-Vmax-4-OH-MDZ-Liver was significantly different than the healthy-Vmax-4-OH-MDZ-Liver  
(Unpaired T-test with P≤0.0001) 
# Day 12-Km-4-OH-MDZ-Liver was significantly different than the healthy-Km-4-OH-MDZ-Liver  
(Unpaired T-test with P≤0.0001) 
 
The IV MDZ clearance decreased by 0.5-fold on day 12 after GPI treatment as compared 
to the healthy mice (P≤0.05) (Table 4.3 and Figure 4.6). By Day 21, the clearance in GPI-treated 
mice had still not returned to values observed in the healthy animals, although the differences were 
not significant (P=0.179). In the case of the PO MDZ administration, the day 12 GPI clearance/F 
was 0.4-fold lower than that of the healthy mice (P≤0.05) (Figure 4.7). 
 
Table 4.3: Pharmacokinetic parameters after IV and PO administration of MDZ 
Route Parameter Unit Healthy mice GPI-treated mice 
on day 12 
GPI-treated mice 
on day 21 
IV Dose mg/kg 1 1 1 
AUC0-8h nM´h 574 (± 71) 1237 (±389)* 723 (±101)NS 
Cmax nM 1260 (± 224) 2493 (±1373) 1289 (±242) 
CL L/h 0.134 (± 0.017) 0.067 (±0.019)** 0.107 (± 0.014)NS 
PO Dose mg/kg 5 5 5 
AUC0-8h nM´h 180 (± 25) 539 (± 199)* 281 (± 78)NS 
Tmax h 0.207 (± 0.071) 0.166 (± 0) 0.207 (± 0.071) 
Cmax nM 224 (± 75) 662 (± 252) 282 (± 51) 
CL/F L/h 2.17 (± 0.34) 0.881 (± 0.47)* 1.474 (± 0.4)NS 
The PK parameters were obtained using NCA and represented as mean (standard deviation). ANOVA and 
Tukey’s test were used for comparison of Day 12 and Day 21 after GPI treatment with healthy mice. *: P≤0.05, 







Figure 4.10:  Comparison of 1-OH-MDZ AUC0-8h for healthy and GPI treated mice after MDZ (left side 
diagram) and PO (right side diagram) administration.  
NS: Not significant, *: P≤0.05, **: P≤0.01 (ANOVA and Tukey’s test for comparison of Day 12 and Day 
21 with Healthy) 
 
 
Figure 4.11: Observed pharmacokinetic profiles for a) IV (1 mg/kg) and b) PO (5 mg/kg) MDZ administration 
Observed MDZ PK represented as filled circles or squares with standard deviation (n=4). 
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4.3.3 Prediction of MDZ PK in GPI-treated mice using the minimal PBPK model 
The Chi square test was used to compare observed PK profile with the predicted profile 
(Figure 4.14). For IV MDZ dosing, the observed and predicted healthy-animal PK profiles were 
similar with a Chi square test p-value of 0.999. While, day 12 observed and predicted PK profiles 
were similar with the Chi square test p-value was 0.996. In the case of PO MDZ dosing, predicted 
and observed profiles in the healthy mice had a Chi square test p-value of 0.999, while day 12 PK 
profiles had Chi square test p-value of 0.964. This indicated that the minimal PBPK model 
successfully predicted the PK after GPI treatment. In addition, AUC0-8h and clearance values of 
MDZ showed good agreement between predicted versus observed values for both the IV and PO 
MDZ administration. The mean observed values of the PK parameters and the 95% confidence 
interval were compared with the predicted PK parameter values. All the predicted PK parameters 
resided within the 95% confidence intervals of the observed data (Figure 4.12 and Figure 4.13). In 
the case of PK predictions after PO dosing on day 12 (Figure 4.14), a visual check showed that the 
data points after 4 h were not well correlated with the predicted profile. This was due to the lack 





Figure 4.12: Comparison of observed and predicted 
PK parameters after IV (1 mg/kg) MDZ 
administration to healthy mice and day 12 after GPI 
treatment obtained using NCA a) AUC0-8h and b) 
Clearance.  
Observed values represented as mean and 95% 
confidence interval. Dashed arrows indicate that the 
PK parameter predicted by the semi-PBPK model 
was within the 95% confidence interval of the 
observed data. 
 
Figure 4.13: Comparison of observed and predicted 
PK parameters after PO (5 mg/kg) MDZ 
administration to healthy mice and day 12 after GPI 
treatment obtained using NCA a) AUC0-8h and b) 
Clearance/F.  
Observed values represented as mean and 95% 
confidence interval. Dashed arrows indicate that the 
PK parameter predicted by the semi-PBPK model 




4.3.4 Sensitivity analysis 
The Cmax was sensitive to both Vmax-1-OH-MDZ-Liver and Km-1-OH-MDZ-Liver after PO MDZ 
administration as demonstrated in the Figure 4.2. Cmax decreased with increasing Vmax-1-OH-MDZ-Liver, 
while increased with increasing Km-1-OH-MDZ-Liver. In addition, altered values of Vmax-1-OH-MDZ-gw, 
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Vmax-NonCYP3A-MDZ-gw, Km-NonCYP3A-MDZ-gw, Fg and Fu,b lead to changes in Cmax and overall PK profile 
of MDZ after PO dosing as shown in the Figure 4.3. 
 
 
Figure 4.14: Observed and the model predicted PK profiles for a) IV (1 mg/kg) and b) PO (5 mg/kg) 
The observed values represented as mean and standard deviation. 
 
Table 4.4: MDZ related and mouse physiological parameters used in the semi-PBPK model 
Parameter Values Source/reference 
Vc (Volume of the central compartment) 0.028 L Estimated* 
Vper (Volume of the peripheral compartment) 0.0411 L Estimated*  
k12 (Rate constant for MDZ transfer from the 
central to peripheral compartment) 6.3944 1/h Estimated* 
k21 (Rate constant for MDZ transfer from the 
peripheral to central compartment) 4.3540 1/h Estimated* 
ka (Rate of absorption from the gut lumen to 
the gut wall) 6.2241 1/h Estimated
# 
Fa (Fraction of the dose absorbed from the gut 
lumen) 1 Kuze et al-2009 (21) 
Fg (Fraction escaped from the gut wall 
metabolism) 0.091 Kuze et al-2009 (21) 
fu,mic (Fraction unbound in the mouse liver 
microsomes)a 0.613 Experimental data 
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B/P ratio 0.813 Cleton et al (34) 
fu,b 0.1008 
Calculated using fu,p and B/P 
ratio 
fu,p (Healthy mice) 0.082 Experimental data 
fu,p (Day 12 after GPI treatment in mice) 0.083 Experimental data 
Qha (Hepatic artery blood flow) 0.786 mL/min Davies and Morris (23), 
Brown et al (24) 
Qht (Total hepatic blood flow) 3.15 mL/min Davies and Morris (23), 
Brown et al (24) 
Qpv (Portal vein blood flow) 2.36 mL/min Davies and Morris (23), 
Brown et al (24) 
Qgw (Gut wall blood flow) 1.5 mL/min Davies and Morris (23) 
*Estimated by fitting the experimental IV healthy animal PK data to the 2-compartment PK model. 
The PK data after 2 h was not included as it was below the limit of quantitation.  
#Estimated by fitting the experimental PO healthy animal PK data to the 2-compartment PK model. 
The PK data after 4 h was not included as it was below the limit of quantitation.  
afu,mic was used to correct the Km obtained from in vitro experiment (Km-Cor=Km × fu,mic) 
fu,b: Fraction unbound in blood, B/P ratio: Blood to Plasma ratio, fu,p: Fraction unbound in plasma 
 
Table 4.5: Model parameters for hepatic and intestinal metabolism of MDZ obtained from the in vitro experiments, 
literature or estimated using the semi-PBPK model 
Parameter (units) Values Source/reference 
 Healthy* Day 12*  
Vmax-1-OH-MDZ-Liver (nmol/h/total liver) 7545 4216 
Experimental in vitro data 
scaled for mouse livera 
Km-1-OH-MDZ-Liver-Cor (nmol/L)b 3432 3739 Experimental in vitro data 
Vmax-4-OH-MDZ-Liver (nmol/h/total liver) 8137 2855 
Experimental in vitro data 
scaled for mouse liver 
Km-4-OH-MDZ-Liver-Cor (nmol/L)b 51001 25991 Experimental in vitro data 
𝑉Q(R	(𝐷𝑎𝑦	12)		
𝑉Q(R	(𝐻𝑒𝑎𝑙𝑡ℎ𝑦)




d Kuze et al-2013 (27) 
Km-1-OH-MDZ-gw-Cor (nmol/L)e 735.6 735.6 Kuze et al-2013 (27) 
Vmax-4-OH-MDZ-gw (nmol/h/total 
intestine)a,c 168 92.4
d Kuze et al-2013 (27) 




Km-nonCYP3A-MDZ-gw (nmol/L) 51571 51571 Estimatedf 
*Values are for the healthy mice or day 12 after GPI treatment to mice 
aScaling of the in vitro kinetics data was done as reported by Barter et al (28) 
b Km-1/4-OH-MDZ-gw-Cor was calculated using formula Km-1/4-OH-MDZ-gw-Cor=Km × fu,mic (35) 
c23.6 milligrams of intestinal microsomal protein per gram of intestine (29) 
dThe ratio of 0.55 was used to calculate Vmax-1OH-MDZ-gw for day 12 after GPI treatment 




Vmax: Maximum rate of metabolic conversion of MDZ to either 1-OH-MDZ or 4-OH-MDZ in 
liver or intestine 
Km: Michaelis-Menten constant representing concentration of MDZ when the rate of 
metabolism is half the maximum value 
fEstimated using the semi-PBPK model for the healthy mice. 
 
Table 4.6: Mouse physiological and MDZ related parameters 
Parameter Value Reference 
Vgl (Volume of the gut lumen) 1.13 mL Kirman et al (25) 
Vgw (Volume of the gut wall) 1.1 mL Kirman et al (25) 
Vpv (Volume of the portal vein) 
(Assumed to be same as that of rat) 
0.55 mL Masyuk et al (26) 
Vliv (Volume of liver) 1.37 mL Brown et al (24) 
F (Oral bioavailability as a fraction) 0.06206 Calculated 
 
4.3.5 Effect of GPI-mediated inflammation on serum cytokine levels 
The cytokine levels peaked on day 12 according to previous experiments (data not shown). 
In this study, the healthy mice had lower cytokine levels as compared to the day 12 GPI treated 
mice (Figure 4.15). Since inflammation in this model remits over time (data not shown), the 
cytokine levels returned to the normal range by day 21, but did not full return to the pre-study 
levels. Serum levels of various other cytokines (IL-2, IL-1β, IL-10, IFN-γ) were not significantly 
elevated on day 12 after GPI treatment (data not shown). IL-6 levels in the GPI-treated mice on 
day 12 were approximately 100-fold higher than that in the healthy mice (P≤0.0001). In addition, 
day 12 IL-6 levels were 5.4-fold higher than that on day 21 (P≤0.0001). However, healthy animal 
and day 21 IL-6 levels were not significantly different. Serum TNF-α levels were 2.6-fold higher 
in diseased animals on day 12 as compared to levels in the healthy mice (P≤0.0001). Day 12 TNF-
α levels were also higher (1.3-fold) than levels on day 21 (P≤0.01). In the case of TNF-α, day 21 




Figure 4.15: Box-plot representation of the serum cytokine levels and statistical comparison for the healthy mice, 
day 12 and day 21 after GPI treatment to mice.  a) IL-6 and b) TNF-α.  
Box-plot showing first and third quartiles, mean and range. NS: Not significant, ****: P≤0.0001, **: P≤0.01 
(ANOVA and Tukey’s test). 
4.3.6 Effect of GPI-mediated inflammation on liver cyp3a11, cyp2c29 and cyp2d26 mRNA 
The mRNA levels of cyp3a11, cyp2c29, and cyp2d26 were normalized to the house-
keeping gene PPIB (Figure 4.16). Cyp2c66 mRNA was not found in this study, while cyp2c29 had 
the highest basal levels of mRNA expression followed by cyp3a11 and cyp2d26. The responses of 
cyp3a11 and cyp2c29 to GPI-mediated inflammation were similar. The mRNA levels were highest 
on day 1 after GPI treatment, followed by a reduction in levels on day 5, and 12 as compared to 
the baseline levels. However, in the case of cyp3a11 and cyp2c29, day 8 showed surprisingly 
increased mRNA levels. On day 15, mRNA levels appeared to increase but did not return to the 
baseline levels. The reduction of mRNA levels was notably highest on day 5. Cyp3a11 mRNA on 
day 12 was suppressed by around 89% after the GPI treatment. On day 12, cyp2c29 and cyp2d26 
mRNA were suppressed by around 85% and 51%, respectively as compared to the day 1 levels.  
 
4.4 Discussion 
In this study, the in vitro metabolism and PK of MDZ was studied to demonstrate 
suppression of the CYP activity in the GPI-treated animals, and a minimal PBPK model was 
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generated using in vitro data from both the healthy and diseased animals. It was assumed that the 
2-compartment IV parameters of the healthy and diseased mice were same. Therefore, the IV-PK 
data from the healthy mice were used to generate the 2-compartmental parameters for both of the 
groups. The 2-comparment model parameters for the disease-animal IV data were also available 




Figure 4.16: Box-plot representation of a) cyp3a11, b) 
cyp2c29 and c) cyp2d26 mRNA levels in mouse livers on 
day 1, 5, 8, 12, and 15 after GPI treatment.  
Box-plot showing first and third quartiles, mean and range. 
NS: Not significant, *: P≤0.05, **: P≤0.01 (Unpaired T-test 
was used to compare mRNA levels on day 1 and day 12). 
 
The GPI mouse model is frequently used to 
induce arthritis and study the anti-inflammatory 
activity of NCEs in the drug discovery process (9). 
In this study, the GPI-mediated inflammation 
increased serum proinflammatory cytokine levels in 
the DBA/1 mice. This result was in agreement with 
the previously published report (8). Several 
published in vitro and in vivo models of 
inflammation showed that increased cytokines can 
lead to reduced CYP expression (10, 11, 36). 
The GPI model showed highest degree of 
inflammation approximately on the day 12 and the 
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inflammation decreased afterwards (data not shown). Therefore, the day 8-CYP mRNA levels 
should be lower as compared to the day 1-levels based on the disease state. Current study shows 
that the mean cyp3a11 and cyp2c29 mRNA levels on day 8 were surprisingly higher as compared 
to the day 5 and 12 (Figure 4.16). However, the day 8-cyp3a11 mRNA levels were not significantly 
different when compared to the day 5 (p=0.1) and day 12 (p=0.13). In the case of cyp2c29 mRNA, 
day 8 and day 12 levels were not significantly different (p=0.054), however, the day 8 mRNA 
levels were significantly higher (p=0.026) than the day 5 (Unpaired T-test). Although the day 8 
mRNA levels could not be completely explained, day 12 data were more important for the 
comparison. Because, CYP mRNA and cytokine levels, in vitro metabolism and PK for day 12 
after GPI treatment were available for day 12 after GPI treatment. Therefore, the conclusions were 
based on the day 12 data.     
The IL-6 and TNF-α proinflammatory cytokine levels increased on day 12 after GPI 
treatment. Cyp3a11 levels decreased on day 5 and 12 after GPI treatment. The reduction in Vmax-
1OH-MDZ-Liver (P≤0.0001) indicated that the CYP activity was suppressed. In this report, the GPI-
mediated inflammation was studied based on increased cytokines, decreased CYP mRNAs, 
decreased in vitro metabolism, and decreased clearance of MDZ. The experimental data may be 
useful for future experiments with GPI-mediated mouse model of inflammation. Another in vitro 
study using human hepatocytes showed that IL-6 was responsible for suppression of various CYP-
mRNA, including CYP3A4. In addition, activities of CYP3A4 and CYP1A2 were also suppressed 
(37). This suppression of CYPs may lead to alteration of PK of its substrates. Machavaram et al 
used the in vitro data of IL-6-mediated CYP suppression in the PBPK model for prediction of 
disease-drug interactions involving elevated cytokine levels. As mentioned previously, serum 
cytokine levels are increased in the inflammatory diseases. Although this elevation of cytokines in 
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the patient population is highly variable and dependent on the disease stage, age, and sleep 
deprivation; it can still impact expression of CYPs (38). In addition, cytokine levels are altered 
due to administration of various therapeutic proteins. For example, blinatumomab, a bispecific 
antibody against CD19, increased cytokines (particularly IL-6 and IL-10) to maximum levels, 
about six hours after administration (6). However, adalimumab, an anti-TNF-α antibody, resulted 
in reduced levels of pro-inflammatory cytokines (TNF-α and IL-6) (39). Since elevated or reduced 
cytokine levels can alter the expression of different CYPs, these biologics have the potential to 
change the PK of the small molecule drugs that are metabolized by the CYPs, resulting in 
therapeutic protein-drug interactions (40). 
Effect of alteration of the model parameters (Vmax, Km, Fg, Fu,b) on the PK profile was 
studied (Figure 4.2 and Figure 4.3). Cmax and AUC (data not shown) were the major PK parameter 
sensitive to the change in various model parameters. This indicates that the tested model 
parameters defined metabolism of MDZ in the liver and intestine and alteration of the values from 
the original parameter value may impact PK prediction of MDZ.     
Plasma protein binding of MDZ is around 95%. Furthermore, the fraction unbound of MDZ 
was constant even with changing plasma drug concentration as reported earlier (41). Alteration of 
plasma proteins may have a significant impact on MDZ clearance assuming that the only unbound 
fraction of MDZ can be metabolized by CYP450 enzymes. A protein binding study with human 
serum albumin and a-1-acid glycoprotein solutions showed that MDZ was extensively bound to 
both (42). Glycosylation of a-1-acid glycoprotein was changed in patients with rheumatoid 
arthritis (43). These structural changes in the protein may lead to altered binding with drugs. In 
another report, plasma albumin levels decreased in patients with the inflammatory disease 
(arthritis). In addition, a-1-acid glycoprotein level increased in the arthritis patients as compared 
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to the healthy control group. The authors also reported changes in the plasma protein binding of 
propranolol and chlorpromazine in the arthritis patients to establish correlation between changes 
in plasma protein levels and protein binding of the drugs (44). Therefore, it was pertinent to 
investigate MDZ protein binding in healthy and GPI-treated mice with inflammation. However, 
MDZ plasma protein binding was same for the healthy and diseased animals (Table 4.4). This 
eliminated the possibility of altered plasma protein levels contributing to differences in clearance 
for the healthy and diseased mice.   
The ‘Well-Stirred’ model (equation 3) of gut (31) was used to calculate fu,g using literature 
values of Qgw, Vmax-1-OH-MDZ-gw, Km-1-OH-MDZ-gw and Fg (Table 4.4 and Table 4.5). After PO 
administration, MDZ is well absorbed (Fa=1) (21). Therefore, low bioavailability (F=0.062) of 
MDZ after PO administration may be attributed to the intestinal metabolism. As mentioned in the 
previous section, in vitro data were not available to define metabolism in the intestines, and hence 
literature values were used instead (27). In addition, non-CYP3A metabolism of MDZ was defined 
by the parameters (Vmax-nonCYP3A-MDZ-gw and Km-nonCYP3A-MDZ-gw) estimated using the minimal PBPK 
model and healthy-animal PK data.   
The 1-OH-MDZ and 4-OH-MDZ are important metabolites of MDZ (13, 15). In a mass 
balance study in humans using radioactive MDZ, 60-70% of administered dose was eliminated via 
renal route as 1-OH-MDZ-glucuronide, while 4-OH-MDZ and 1,4-diOH-MDZ were ~3 and ~1%, 
respectively. Urinary excretion of unchanged MDZ was negligible (45). Another study used rats 
to show that 81% of the administered dose was recovered in the feces, while 10% was recovered 
in the urine (46). In addition, urinary excretion of MDZ had <1% contribution according to a 
clinical study (47). Therefore, in this study, renal clearance of MDZ was excluded from the model. 
The model substrate MDZ, is mainly cleared via hepatic metabolism. For other drugs with 
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minimum or no hepatic metabolism where renal elimination is a major route of clearance, the 
minimal PBPK model may not be appropriate or may need modifications to account for non-
hepatic metabolism and renal elimination. In addition, the model would require PK data generated 
in the healthy animals and hepatic in vitro microsomal metabolism data obtained using both the 
healthy and diseased mice. 
Overall, the model successfully predicted MDZ PK in the disease condition. The model 
may be useful to predict PK of other CYP substrates in the mice with GPI-mediated inflammation. 
In the drug discovery process, dose selection for the preclinical disease models is usually done 
using PK data in the healthy animals. The healthy animal PK data may not accurately predict the 
impact of inflammation or other diseases on the PK of NCEs. The minimal PBPK model may be 
useful to predict doses for achieving targeted exposure during GPI-mediated inflammation. The 
model and in vitro data were used to demonstrate this approach of PK prediction. However, the 
proposed framework of the minimal PBPK model may also be extended to other inflammation 
models and disease conditions, provided availability of minimal healthy animal PK and in vitro 
metabolism data that assumes clearance via CYPs.  
 
4.5 Conclusion 
The in vitro hepatic metabolism, and PK of MDZ were studied during the GPI-mediated 
inflammation in mice. In addition, serum cytokine levels and hepatic CYP mRNA during GPI-
mediated inflammation were examined. The minimal PBPK model predicted PK of MDZ in the 
diseased state. The model may be used to select doses for mice with GPI-mediated inflammation 
in order to achieve targeted exposure by correcting for suppression of metabolism due to 
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inflammation. This model may also be used for PK prediction of other drugs after GPI-mediated 
inflammation. 
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Glossary 
Parameter Definition 
𝐴_` Amount of MDZ in the gut lumen compartment 
𝐹( Fraction of the dose absorbed from the gut lumen 
𝑘( Rate of absorption from the gut lumen to the gut wall 
𝑉_a Volume of the gut wall 
𝑉)z Volume of the portal vein 
𝑉 |z Volume of liver 
𝑉{/0 Volume of the central compartment 
𝐶_a Concentration of MDZ in gut wall 
𝐶)z Concentration of MDZ in portal vein 
𝐶{/0 Concentration of MDZ in central compartment 
𝐶`|z Concentration of MDZ in liver 
𝐶)/4 Concentration of MDZ in peripheral compartment 
𝑄_a Gut wall blood flow 
𝑄)z Portal vein blood flow 
𝑄2\ Total hepatic blood flow 
𝑄2( Hepatic artery blood flow 
𝑘MN Rate constant for MDZ transfer from the central to peripheral 
compartment 
𝑘NM Rate constant for MDZ transfer from the peripheral to central 
compartment 
𝐹_ Fraction escaped from the gut wall metabolism 
𝑓I,_ Fraction unbound in gut 
𝑓I,. Fraction unbound in blood 
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𝑉Q(R+M+mn+opq+_a Maximum rate of metabolic conversion of MDZ to 1-OH-
MDZ in gut wall 
𝐾Q+M+mn+opq+_a Michaelis-Menten constant representing concentration of 
MDZ when the rate of 1-OH-MDZ formation is half the 
maximum value in gut wall 
𝑉Q(R+r+mn+opq+_a Maximum rate of metabolic conversion of MDZ to 4-OH-
MDZ in gut wall 
𝐾Q+r+mn+opq+_a Michaelis-Menten constant representing concentration of 
MDZ when the rate of 4-OH-MDZ formation is half the 
maximum value in gut wall 
𝑉Q(R+030#*Ox-+opq+_a Maximum rate of metabolic conversion of MDZ for additional 
nonCYP3A metabolism 
𝐾Q+030#*Ox-+opq+_a Michaelis-Menten constant representing concentration of 
MDZ when the rate of nonCYP3A metabolism is half the 
maximum value in gut wall 
𝑉Q(R+M+mn+opq+'|z/4 Maximum rate of metabolic conversion of MDZ to 1-OH-
MDZ in liver 
𝐾Q+M+mn+opq+'|z/4 Michaelis-Menten constant representing concentration of 
MDZ when the rate of 1-OH-MDZ formation is half the 
maximum value in liver 
𝑉Q(R+r+mn+opq+'|z/4 Maximum rate of metabolic conversion of MDZ to 4-OH-
MDZ in liver 
𝐾Q+r+mn+opq+'|z/4 Michaelis-Menten constant representing concentration of 
MDZ when the rate of 4-OH-MDZ formation is half the 
maximum value in liver 
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Chapter 5 : Future Directions 
The lymphatic trunk-LN clearance was estimated using the top-down minimal PBPK 
model (Chapter 2). The model indicates that the LNs are mainly responsible for proteolysis of 
mAbs. Therefore, LN cell suspension can be used in the future to measure the rate of mAb 
clearance. In addition, the in vitro methods representing the SC tissue should be developed to 
understand mechanism of mAb loss leading to their reduced bioavailability. The minimal PBPK 
model may be used as a platform to include the in vitro clearance data for prediction of SC PK.  
The SC injection site lymph flow, afferent lymph flow, efferent lymph flow, volumes 
associated with the SC injection site, thoracic duct lymph flow were important physiological 
parameters governing the absorption of mAbs. However, further research is needed to understand 
the transit of mAbs via SC tissue and lymphatic system. For example, in this study, the lymphatic 
capillary network and lymphatic trunk volumes were approximately measured based on the 
literature information. However, the clinical data indicating the lymphatic distribution of mAbs 
after SC administration can help to modify the model volumes. In addition, the physiological 
parameters are variable across the population and can change due to physical stress. Therefore, 
detailed investigation about impact of the disease conditions, populations, species and exercise on 
various lymph flows and volumes is necessary. The top-down approach should also be used for 
other types of mAbs (e.g. IgG2, IgG4) and TPs (e.g. peptides, growth hormone, insulin). The 
model estimated lymphatic trunk-LN clearance increased with increase in the pI of the mAbs. 
Furthermore, the relationship of the estimated clearance and pI should be verified using other TPs.      
In Chapter 3, effect of IONPs on degree of the oxidation and secondary structure of rGH 
was evaluated. The IONPs decreased H2O2- and AAPH-mediated oxidation. This could indicate 
that the rGH corona was possibly formed around the IONPs. Hence, rGH was protected against 
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the induced oxidation. However, this phenomenon should be verified using other combinations of 
TPs and metal nanoparticles. Furthermore, the a-helical structure of rGH was altered in the 
presence of IONPs. It should be investigated if the IONPs can change the secondary structure of 
other proteins having predominant b sheets, b turns or W loops.  
In Chapter 4, the minimal PBPK model predicted PK of MDZ (a standard CYP substrate) 
during the GPI-mediated inflammation. However, the PK and in vitro metabolism of standard 
substrates of other CYPs must be evaluated. This would potentially help to predict PK in the 
disease state for NCEs metabolized by various CYPs. Furthermore, the cytokine measurements at 
various stages of the GPI-mediated inflammation may be correlated mathematically with the 
suppression of CYP mRNA and functional impact on the in vitro metabolism and PK. It is possible 
to predict the PK of NCEs (metabolized by the CYPs), based on the known suppression of the 
CYP mRNA, and elevation of serum cytokines during the disease.  
 
 
